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There is a significant need for small diameter vascular grafts to be used in peripheral vascular surgery; 
however autologous grafts are not always available, synthetic grafts perform poorly and allografts and 
xenografts degenerate, dilate and calcify after implantation.  We hypothesized that chemical stabilization of 
acellular xenogenic arteries would generate off-the-shelf grafts resistant to thrombosis, dilatation and 
calcification.  To test this hypothesis, we decellularized porcine renal arteries, stabilized elastin with penta-
galloyl glucose and collagen with carbodiimide/activated heparin and implanted them as transposition grafts 
in the abdominal aorta of rats as direct implants and separately as indirect, isolation-loop implants.  All 
implants resulted in high patency and animal survival rates, ubiquitous encapsulation within a vascularized 
collagenous capsule, and exhibited lack of lumen thrombogenicity and no graft wall calcification.  Peri-
anastomotic neo-intimal tissue overgrowth was a normal occurrence in direct implants; however this reaction 
was circumvented in indirect implants.  Notably, implantation of nontreated control scaffolds exhibited marked 
graft dilatation and elastin degeneration; however, PGG significantly reduced elastin degradation and 
prevented aneurismal dilatation of vascular grafts.  Overall these results point to the outstanding potential of 
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Section I - 
 




The treatment of symptomatic peripheral arterial disease (PAD) centres around the surgical revascularisation 
of ischaemic tissue.  Although minimally-invasive techniques provide an attractive solution, open surgical 
bypass of the occluded vessel is the gold standard for achieving reperfusion[1], [2].  Despite six decades of 
research focussing on the development of a synthetic alternative, autologous tissue remains the conduit of 
choice for this procedure[3].  Both arterial (internal mammary, radial and gastro-epiploic artery) and venous 
(saphenous and basilic) grafts are used in cardiovascular applications, with veins being the conduit of choice 
in PAD[1], [2].  The advantages of autologous implants include their resistance to infection as well as long 
term patency, but their use is limited by availability and harvest morbidity, prompting the search for synthetic 
option. 
 
Contemporary synthetic materials perform adequately in medium to large diameter vessels (≥6mm), but the 
use of a satisfactory small-diameter conduit remains inappropriate due to acute thrombotic occlusion and 
chronic anastomotic overgrowth in the form of intimal hyperplasia[4].  Initial research in vascular grafts 
focused on developing non-reactive substances to limit the host response.  More recently, the goal has 
shifted to integrating biological materials within the circulatory system through tissue engineering[5].  This 
form of regenerative medicine integrates both absorbable as well as non-degenerating materials to organise 
cells in a coherent arrangement within a scaffold[6].  The degree of tissue engineering can range from a 
single layer of cells to the high complexity of a solid organ[7].  Despite advances in other organ systems, a 
clinically applicable tissue engineered blood vessel does not yet exist. 
 
The concept of decellularization aims to separate all cellular material and antigenic debris from the donor 
vessel extracellular matrix (ECM) to create an inert tube that also functions as a scaffold for tissue 
ingrowth[8].  This process simplifies the tissue engineering requirements by providing a pre-existing construct 
for host cellular ingrowth.  Ultimately, the objective is to develop a vascular graft from a decellularized 
xenogeneic tissue for treatment of small vessel occlusion. 
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2. Peripheral arterial disease 
 
PAD is a diffuse atherosclerotic arteriopathy that is a clinical manifestation of chronic arterial occlusion 
defined by a pulse pressure differential between the upper and lower limb[9], [10].  This progressive vascular 
disorder is initiated by high plasma concentrations of low-density lipoprotein, which incite an inflammatory 
process resulting in vessel occlusion[11], [12].  PAD is associated with significant morbidity, but peripheral 
arterial occlusion does not itself result in death.  However, it is a marker of systemic atherosclerosis and is 
associated with coronary artery disease and myocardial infarction[13].  Therefore, the management should 
involve a holistic approach that addresses risk modification and secondary prevention.  The treatment of 
hyperlipidaemia, diabetes mellitus and hypertension as well as ensuring smoking cessation and the 
implementation of anti-platelet therapy, are fundamental to prevent atherosclerotic progression[1], [2].  Limb 
specific management focuses on revascularisation for symptom relief from vascular insufficiency ulcers as 
well as pain in the form of claudication.  More importantly the goal is to prevent loss of the diseased limb, 
which has a five yearly risk of 1.0-3.3% [14]. 
 
A third of the 27 million patients in the USA diagnosed with PAD are symptomatic requiring some form of 
medical intervention[15], [16].  Although the full extent of atherosclerotic disease in Sub-Saharan Africa is 
not yet defined, a recent increase in the incidence has had a significant impact on the heath system[17].  
Similarly, the incidence in South Africa is estimated to be in line with global reporting based on small 
observational studies[16], [18]. 
 
The management of symptomatic PAD is dependent on the revascularisation of ischaemic tissue through 
arterial bypass[1], [2].  The femoropopliteal segment is the most commonly treated infra-inguinal artery, and 
open bypass with autologous saphenous vein is the standard of care with best patency and limb salvage 
rates.  However, autologous tissue is unavailable up to 40% of the time, requiring a synthetic alternative[19].  
Despite less than satisfactory results for current synthetic implants (40% patency at 5 years) there is no 
superior alternative[20].  Although endovascular approaches have also been applied for PAD, stenting 
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remains controversial in distal disease despite the established indication in more proximal aortoiliac disease.  
Thus the challenge remains since contemporary designs remain inadequate for small diameter vessel 
reconstruction. 
 
3. Contemporary Vascular Grafts 
 
In the absence of autologous material, synthetics have been implanted as an arterial substitute for vascular 
reconstruction.  There are currently two widely used materials as vascular conduits: Polyethylene 
terephthalate (PET) and Polytetrafluoroethylene (PTFE), which have created separate niches within vascular 
surgery in the absence of evidence to support their differential use[21], [22]. 
 
The combination of ethylene glycol and terephthalic acid form a thermoplastic resin known as PET 
(Terylene®, Dacron®)[23], [24].  PET vascular grafts are constructed as a textile tube in a woven or knitted 
form as a multifilament yarn that has a tensile strength of 170 MPa and modulus of 14 000MPa[25].  The 
conduit can be further supported by spirals or crimped to improve radial strength and kink-resistance.  
Despite the concern that knitted PET has a tendency to dilate under arterial pressure, few clinical 
complications have been reported and no clinical difference has been demonstrated between the knitted or 
woven designs[21], [26].  The textile nature of PET allows for bifurcating grafts and large diameter 
constructions and by further adding velour techniques, tissue ingrowth can be optimised.  As a result PET has 
become the conduit of choice for medium to large diameter grafts[27]. 
 
PTFE (Gore-Tex®, Teflon®) is a inert fluorocarbon that can be expanded in to a porous form known as 
ePTFE[4], [26].  It is moderately stiff (100 MPa) with a lower tensile strength than that of PET (14MPa)[25], 
but highly flexible and permeable to gases.  PTFE was initially trialled as a textile, but has been exclusively 
implanted as ePTFE since 1972[28]. Porosity is determined but the internodal distance (distance between 
the solid nodes created in the extrusion process), where distances less than 30µm are referred to as low 
porosity and those greater than 45µm as high porosity graft.  The majority of clinical implanted ePTFE grafts 
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are marketed as 30µm IND and the graft is predominantly used in medium to small vessel positions. 
 
Although these synthetic grafts have been used successfully in large calibre arteries with an acceptable long-
term outcome, the intrinsic thrombogenicity of these materials and compliance mismatch leads to poor short 
and long term outcome in small to medium vessels.  Short term results of biological grafts have been 
promising but have failed beyond one year due to calcification and aneurysmal dilatation.  The challenge 
remains to develop biological grafts that maintain long term patency through optimisation of graft properties. 
 
4. Properties of vascular grafts 
 
Vascular graft development aims to maintain a stable conduit with long term patency[29].  However, this goal 
has been referred to as a ‘holy grail’ due to the inherent complexities of integrating synthetic material in a 
dynamic circulatory system[30].  Inappropriate patient selection, surgical technique[31] and calibre 
mismatch[32] may contribute to graft failure, but the multifaceted interaction between host vessel and the 
graft accounts for the majority of vessel occlusion. 
 
Graft design has to allow for the physical demands (burst pressure, compliance and suture retention) as well 
as biocompatibility of all surface interactions when implanted in the circulation.  This strength of a conduit is 
defined by the ‘burst pressure’, which is measured by exposing the graft to increasing hydrostatic forces[33].  
The moment where the closed system measures a sharp drop in pressure, represents mural compromise and 
graft failure.  Carotid arteries and saphenous veins have a burst pressure of 5000mmHg and 2250mmHg 
respectively, but 300-500mmHg is regarded as the minimum requirement for a synthetic arterial implant[34].  
Since wall tension is proportional to the diameter and wall thickness of a cylinder (law of La Place), small 
diameter grafts require significantly higher pressures to exert the same amount of force.  As a result, burst 
pressures are seldom a limiting factor in grafts less than six millimetres in diameter.  Mural weakness 
resulting in aneurysmal dilatation of small diameter grafts is however a well documented phenomenon and 
the aetiology is multifactorial.  In bioprosthetic implants the degradation of elastin and collagen by matrix 
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metalloproteinases (MMPs) initiate mural weakening and dilatation.  Synthetic grafts are largely resistant to 
degradation, unless specifically designed to do so as in the case of degradable polymers.  However, 
aneurysmal dilatation may still occur due to inherent structural design flaws, such as in knitted textiles[26] 
and unwrapped ePTFE grafts[35].  This is of particular concern since aneurysmal dilatation leads to an 
exponential rise in wall tension, increasing the risk of graft rupture. 
 
Compliance of a vessel or conduit is defined by the change in diameter between systolic and diastolic 
pressure[36].  An artery is usually exposed to a pulse pressure variation of 40mmHg with 10-15% 
compliance.  Although blood vessels have non-linear elastic properties and stiffen with increasing pressures, 
their maximal compliance is within the physiological blood pressure range and is significantly higher than 
contemporary synthetic grafts[25].  This interaction between the native vessel and implanted conduit results 
in a compliance mismatch with anastomotic flow disturbance.  This turbulent flow results in endothelial cell 
damage that triggers tissue remodelling and ultimately intimal hyperplasia[36], [37].  Thus an aim of conduit 
development would be to construct a graft with a compliance profile that matches the host artery to limit 
perianastomotic hyperplasia. 
 
Suture retention strength has been documented as an important feature of a vascular graft design.  It is a 
logical prerequisite as sutures are required to anastomose the graft in position, but as yet, no literature has 
determined the ideal or adequate conditions required for an implant[38].  Current literature describes suture 
retention forces by measuring the force required to avulse the experimental material[39], [40].  However, the 
authors seldom mention the calibre of the suture or alternatively reference a suture which is too large for 
clinically applicable anastomosis.  As a result the literature predominantly reports on bench in vitro studies, 
which lack reproducibly, and seldom report specific suture strength requirements. 
 
When one refers to biocompatibility, it is clear that the graft should be resistant to infection, non-toxic, non-
allergic and not induce malignancies[4], [39], [40].  However, acute occlusion due to thrombosis has been 
the primary focus of graft modification.  It is well established that all foreign materials in the circulatory system 
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are inherently thrombogenic and induce the coagulation cascade following the blood-surface interaction[41].  
Thrombogenicity can in part be manipulated by altering the graft surface with biologically active compounds.  
The most successful treatment thus far has been heparin modification though covalent surface bonding to 
ePTFE grafts[42], [43], and is well established in the manufacture of cardiopulmonary bypass circuits.  The 
manipulation of the surface with nitric oxide (NO) modification has also shown potential advances in the 
prevention of thrombosis as well as the down regulation of endothelial adhesion molecules and inhibition of 
smooth muscle proliferation[44].  Although the alteration of graft host interaction with compounds such as NO 
have theoretical advantages, they are currently impractical due to the finite reservoir[45], and potential 
carcinogenic nitrosamine formation[46]. 
 
In summary the lack of progress in synthetic vascular graft development over the last 60 years has resulted in 
specific modifications attempting to address isolated aspects of graft failure.  However, the physical and 
biological attributes mentioned above are often intertwined and interdependent.  As a result, the focus may 
require a shift away from contemporary graft modifications and optimisation towards novel biosynthetic 
designs. 
 
5. Experimental solutions 
 
Experimental graft designs have predominantly focused on two concepts; degradable synthetic polymer 
scaffolds and tissues engineering. 
 
a) Degradable polymers 
The design objective of total polymer resorption aims to avoid the persistent foreign body reaction seen in all 
non-degradable counterparts.  The synthetic materials are referred to as biodegradable when enzymatically 
degraded or bioabsorbable when non-enzymatic chemicals breakdown the polymer.  The challenge in design 
is to limit graft fragmentation and embolization of the degraded polymer whilst maintaining sufficient strength 
through tissue ingrowth before the degradation process results in graft failure[21], [47]. 
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Polyglycolic acid (PGA) was the first degradable synthetic suture material, but due to is rapid loss of strength, 
could not be used for vascular graft applications[48].  PGA was subsequently methylated to form a more 
hydrophilic compound known as polylactic acid (PLA) and the first fully bioresorbable vascular graft was 
constructed out of a PGA-PLA copolymer known and polyglatin (Vicryl-PG910) [49].  Despite the initial 
enthusiasm with polyglactin, as with previous degradable polymer grafts it is also prone to aneurysmal 
dilatation and rupture.  Other materials which are used clinically as sutures (polyhydroxyalkanoate, 
polycaprolactone and polydioxanone) have not progressed beyond clinical trials as vascular conduits despite 
histological evidence of intermediate stability[6]. 
 
b) Tissue Engineering 
First attempts of tissue engineering involved endothelial cell transplant onto the luminal surface of permanent 
scaffolds to create a ‘natural’ barrier between the blood and synthetic material[50].  This process requires 
harvesting of autologous endothelial cells, which are applied to the polymeric surface immediately before 
implant as a single stage process, or alternatively as a two stage procedure following cell culture.  Despite 
trial evidence of infra-inguinal patency equivalent to that of autologous veins in two -stage seeded 
ePTFE[51], the extreme cost and high level of expertise required to implement this technique has limited its 
clinical application.  These constraints have not deterred researchers who continue to explore scaffold free, 
complete tissue engineering of the vessel, an even more complex form of tissue engineering. 
 
More recently the concept of completely tissue engineered blood vessels (TEBV) has been proposed as a 
surrogate for autologous tissue[52], [53].  Their ability to remodel and repair as an autologous graft would do 
without a foreign body response has renewed enthusiasm as a viable alternative despite its rigorous 
demands.  The concept relies on ex vivo cell culture to construct the vessel in a pulsatile bioreactor using a 
degradable material as a scaffold.  Initially acellular collagen and PGA based degradable scaffolds were 
used, but neither of these techniques have been able to sustain systemic pressures.  Recent optimisation 
with staged culture layers has resulted in the first clinical trial of a TEBV[54].  The process involves 
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dehydrated human skin fibroblasts, which are wrapped around a PTFE mandrill followed but the culture of an 
umbilical smooth muscle cell-wrap to form the media.  Following a week long culture in a bioreactor, 
fibroblasts are added to create an adventitia and the surface is subsequently seeded with endothelium[55].  
Despite excellent clinical patency of the TEBV, as with seeded ePTFE, these designs have not made any 
penetration beyond clinical trial due to extreme expense and expertise required to develop these models[56].  
A more practical solution would therefore employ the concept of the human body as a bioreactor for a natural 
scaffold that would allow for in vivo tissue regeneration. 
 
c) Decellularization 
 The inflammatory response and an immune mediated rejection initiated by antigenic remnants found in 
foreign tissue, remains an inherent challenge in cross-species implants[57].  In an attempt to replicate the 
performance of autologous tissue, researchers have eliminated these cellular products from xeno- and 
allograft tissues[58].  Unlike TEBV, this process of decellularization is a ’top-down’ approach of modifying 
naturally occurring scaffolds rather than de novo construction and is thus significantly less complex or 
costly[33]. 
 
Following the removal of cellular material, a complex structure comprising of collagen and elastin remains 
that represents the ECM.  This scaffold is generally non-immunogenic[59], but still provides a role for cellular 
migration, proliferation and differentiation[60].  The process of decellularization uses a combination of 
physical and chemical treatments to eliminate all cellular and nuclear materials from the tissue, with the 
minimal possible disturbance of mechanical integrity.  Physical methods include freeze-thawing or direct 
pressure lysis to destabilise cellular membranes, which are often precursors to further chemical treatment.  
Other methods such as mechanical agitation and sonication are used simultaneously with chemical 
treatments to assist cell lysis and removal of debris. 
 
A vast array of chemical treatments have been applied in the degradation of cellular materials and their 
utilisation is dependent on tissue characteristics as well as clinical application[60]: These range from 
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detergent based treatments (pH manipulation, non-ionic, ionic and zwitterionic detergents), Osmotic shock 
treatments (hypo- and hypertonic) as well as chelating agents.  Enzymatic methods and protease inhibitors 
although not strictly speaking chemical treatments, are often grouped to together with the other ‘non-physical’ 
treatments.  It is essential to ensure that the tissue has been adequately decellularized and verification can 
be performed with standard histological staining (haematoxylin and Eosin and Masson’s trichrome stains) and 
specific immunohistochemical methods, which stain for intracellular proteins.  DNA staining with DAPI is a 
standard method for verifying the absence of nucleic acids. 
 
Although the ECM is responsible for maintaining structural strength, any process that involves the removal of 
cells will ultimately reshape the three-dimensional structure of the ECM and potentially compromise stability.  
As a result untreated scaffolds tend to degenerate rapidly after implantation if they are not adequately 
stabilised[61].  Gluteraldehyde has been widely used as a tissue fixative to stabilise, sterilise and reduce 
antigenicity of tissue[62].  The di-aldehyde bonds of gluteraldehyde react with the free amine groups on the 
ECM, more specifically collagen, and cross-link to strengthen the tissue.  Although collagen cross-linking 
adds strength, the tissue is more prone to calcification following gluteraldehyde fixation and since elastin 
devoid of amine groups, it remains untreated allowing for enzymatic degradation of this important molecule.  
It is clear that current tissue fixation techniques require optimisation.  Novel research with tannic acids such 
as pentagalloyl glucose(PGG) have been shown to specifically bind to elation and render it resistant to the 
enzymatic degradation and aneurysm formation[63]. 
 
 Pre-clinical and human applications of decellularized tissues have already been implanted in other 
positions[58], [64], [65], but have yet to be successfully implemented as vascular conduits.  It is clear that 
researchers need to employ decellularization techniques that limit the damage to the ECM integrity whilst 
ensuring the removal of all antigenic material.  Novel stabilisation techniques the preserve the function of both 
elastin and collagen are essential for long-term patency and structural integrity. 
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6. In vivo model designs 
 
Novel conduit development has relied on in vivo animal implants to clarify compatibility and identify graft-host 
interactions[66].  Not only are pre-clinical implants a requirement for regulatory approval prior to a clinical 
trial, the in vivo simulation provides researchers with information that would not be available through ex vivo 
bench testing.  It is however essential to select an animal model that provides the appropriate anatomy, 
physiology and pathological environment for human extrapolation and implementation.  It is clear that the 
primate would be the logical choice if only to fulfil the above requirements, but the ethics and financial 
implications of primate based research has largely rendered this model obsolete.  As a result, other large 
animal models (ovine, porcine and canine) dominate the literature, but even these have significant cost 
implications if not implemented appropriately.  The high-throughput, cost effective small animal model has 
been widely used as a screening tool, preceding the large animal implant. 
 
The rat is widely established as a circulatory model with many similarities to the haemodynamic profile of 
humans.  A blood pressure of 127±7mmHg (systolic) and 85±2mmHg (diastolic) is ideal to simulate a human 
implant and the ‘supra-normal’ heart rate of 250 to 450bmp exposes the graft to four times the cycles that a 
human graft would endure over the same time period[66].  An 18 month rat experiment is considered the 
entire lifespan of the animal with accelerated aging compared to a human[67]. It is postulated that the rapid 
metabolic turnover would represent a long-term implant in a human although the exact haemodynamic 
consequences of this high heart rate can only be extrapolated from other haemodynamic data. 
 
Haemodynamic factors, such as: flow (mL/min), velocity (cm/s) and wall shear stress (dynes/cm2) have an 
effect on conduit and cellular function.  Although there appears to be a direct linear correlation between 
blood-flow and animal size, the velocity of blood remains static with respect to species[66].  A second factor 
is the variation in flow between arterial sites, within the same species.  For example, there is a direct 
relationship between carotid artery flow and body mass, which is not observed in the femoral artery.[68]  
However, these data are heterogeneous and dependent on the method of measurement as well loading 
 16 
conditions during anaesthesia [69]. 
 
Although also subject to the same variability, wall shear stress has significant effect on vascular graft healing 
and endothelial adhesion molecules[70] as the tangential component of frictional forces generated at the 
vessel surface have been shown to affect healing and cellular interaction[68].  The endothelium endure most 
of the wall shear stress and recent studies have shown that flow disturbances are responsible for 
atherogenesis and plaque formation[71]  The magnitude of shear stress is directly proportional to the 
viscosity of blood, which remains relatively constant across species, but is inversely proportional to the radius 
of the vessels.  It is for this reason that shear stress is directly proportional to species size.  Human arteries 
have a shear stress of 10 to 70 dyn/cm2 [71], [72], whereas the shear stress in the rodent aorta is tenfold 
higher with measurements up to 600dyn/cm2 [73].  This significantly higher shear stress would have 
implications not only for the ability of endothelium to remain attached to the surface of a synthetic conduit, but 
would also limit the adhesion of platelets further reducing the thrombogenicity of the implanted foreign 
material.  Observations have however shown that vascular remodelling is dependent on the change in shear 
stress rather than the absolute value[74], [75], and thus the impact of this interspecies variability remains 
speculative. 
 
Furthermore, the rat has a significantly less demanding coagulation cascade than other mammals which 
results in significantly higher patency.  Although this may be of benefit for assessing prototype graft designs, 
investigators are often frustrated by poor graft performance when implanted in larger animals.  It is for this 
reason that rats should not be used for thrombogenic models but for evaluating physical properties and 
healing.  Further consideration has to be given to the age of the animal, with particular reference to the 
intended implant age of the index human patient.  PAD predominantly affects senescent individuals, which 
would impact on the regenerative potential in clinical practise.  Synthetic graft healing has been shown to be 
less effective in older animals, which is likely to be mirrored in the clinical implant into aged human patients.  
This data is however not linear and interpretation is complex due to the heterogeniticy of techniques used to 
measure healing[76].  This further complicated by cross-species variation, with juvenile baboons displaying 
 17 
similar healing characteristics to senescent dogs[29].  It is clear that every animal model has limitations, 
which should be carefully considered when interpreting the data.  The challenge therefore is to choose the 
appropriate model to answer the research question posed and ensure that it is fully optimised to deliver the 
appropriate result. 
 
Few animal models employ representative graft lengths and this is of particular relevance in the rat.  A mean 
length of 18.1±26.6mm [2-100mm) is reported in the literature.  As a result 90% of grafts are too short to have 
clinical relevance in PAD[29].  The 10% that are of adequate length are looped within the abdomen to 
increase the length of the infra-renal segment[77].  But even lengths of 10cm are too short to adequately 
simulate clinically implanted graft for PAD, which are as long as 40cm[29].  It is however possible to simulate 
mid-graft healing by isolating it from the anastomosis allowing for independent analysis.  Mid-graft isolation 
models have been implemented successfully in large animal model[78], but the recent application of a looped 
isolation model in the rat has allowed for high throughout endothelial analysis[79]. 
 
The combination of looping an infra-renal graft and isolating it from the anastomosis allows the research to 
independently assess transanastomotic as well and mid-graft healing of the experimental model.  By 
implementing this philosophy in a small animal model such as a rat one is able to inexpensively asses healing 




PAD is a global pandemic with an increasing incidence in the developing world.  Despite efforts to limit the 
progression of the disease through primary and secondary prevention, symptomatic patients still require open 
surgical bypass for pain relief and limb salvage.  Vascular graft research has stagnated over the last sixty 
years with little alternative to autologous vein bypass of the occluded peripheral artery.  Despite a renewed 
focus on tissue engineering with promising results from TEBV, the translation from the laboratory to the clinic 
remains elusive.  A simplified concept of tissue engineering where the pre-existing ECM construct is isolated 
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through decellularization appears to be a logical solution to this complex obstacle.  More importantly in vivo 
models need to be designed to analyse both anastomotic interaction as well as mid-graft healing and the 
implementation of isolated mid-segments are essential in high throughput rodent models.  It is with the 
combination of a simplified tissue engineering concept together with an appropriate model design that will 
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There is a significant need for small diameter vascular grafts to be used in peripheral vascular surgery; 
however autologous grafts are not always available, synthetic grafts perform poorly and allografts as well 
as  xenografts degenerate, dilate and calcify after implantation.  We hypothesized that chemical stabilization 
of acellular xenogenic arteries would generate off-the-shelf grafts resistant to thrombosis, dilatation and 
calcification.  To test this hypothesis, we decellularized porcine renal arteries, stabilized elastin with penta-
galloyl glucose and collagen with carbodiimide/activated heparin and implanted them as transposition 
grafts in the abdominal aorta of rats as direct implants and separately as indirect, isolation-loop implants.  All 
implants resulted in high patency and animal survival rates, ubiquitous encapsulation within a vascularized 
collagenous capsule, and exhibited lack of lumen thrombogenicity and no graft wall calcification.  Peri-
anastomotic neo-intimal tissue overgrowth was a normal occurrence in direct implants; however, this 
reaction was circumvented in indirect implants.  Notably, implantation of nontreated control scaffolds 
exhibited marked graft dilatation and elastin degeneration; however, PGG significantly reduced elastin 
degradation and prevented aneurismal dilatation of vascular grafts.  Overall these results point to the 




Almost 1.4 million vascular grafts are needed every year in the US alone to replace diseased arteries.  Of these, 
about 200,000 are small and medium diameter grafts (4-6 mm) for vascular access and to relieve lower limb 
ischemia and more than 600,000 are small diameter grafts (1-4 mm) needed for coronary bypass procedures.  
The conduit of choice for small diameter vascular graft surgery is the autologous vein or artery, but these are not 
available in 25-30% of patients due to preexisting conditions or previous harvesting [1].  Current grafts are 
made of polyethylene terephtalate (Dacron) or expanded polytetrafluoroethylene (ePTFE), or biologically 
derived conduits such as cryopreserved saphenous vein allografts and decellularized bovine ureters [2,3].  
Synthetic grafts are being used successfully for replacements of large caliber arteries (above 8 mm internal 
diameter) with acceptable long term patency [4].  However, when the same materials are used in small 
diameter applications (less than 6 mm internal diameter), they perform very poorly as peripheral arteries, 
with 50% of them occluding within 5 years, potentially leading to amputation.  This is due to the intrinsic 
thrombogenicity of the materials, significant compliance mismatch leading to peri-anastomotic intimal 
hyperplasia and lack of remodeling and growth when implanted in young patients [5].  Short term results of 
biological grafts are also quite promising, but despite their “off the shelf” appeal, poor 1-year patency, extended 
thrombosis, aneurysmal degeneration leading to rupture and calcification have limited the use of such conduits 
[6].  This daunting lack of options has prompted surgeons to implant small diameter vascular grafts made of 
synthetic polymers with suboptimal results. 
 
Therefore, surgeons welcome the possibility of gaining access to “off-the-shelf” small diameter grafts that 
would be easy to suture, exhibit adequate compliance and burst pressures, remain patent and resist 
thrombosis and be resistant to aneurismal degeneration and calcification.  It is believed that tissue 
engineering has the potential to generate such viable grafts by combining synthetic or naturally derived 
degradable or non-degradable scaffolds with a variety of cells followed by maturation in bioreactors.  Such 
constructs have been tested in animal models but few of them have reached clinical trials because of their 
tendency to degenerate, dilate and calcify after implantation [6-9]. 
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To overcome aneurismal degeneration and dilatation, we hypothesized that superior vascular graft 
scaffolds can be produced by chemically stabilizing acellular arteries.  To test this hypothesis, we pioneered 
the use of elastin-rich tubular vascular grafts (ETVGs) produced from porcine arteries from which all cells and 
most of the collagen has been selectively removed.  This approach has the advantage of creating a 3-D 
porous structure and maintaining native tissue architecture and arterial matrix “niche” while removing xeno-
antigens.  We were also the first to describe treatment with pentagalloylglucose (PGG) an elastin-
stabilizing polyphenolic tannin to reduce biodegradation and calcification of ETVGs [10-12].  In addition we 
showed that PGG-treated ETVGs exhibited adequate mechanical and biological properties in vivo by 
subdermal implantation and were non-thrombogenic in acute implantation studies in rabbits [13,14]; 
recently we also showed that PGG treatment diminished the tendency of ETVGs to undergo diabetes-related 
alterations in vivo [10] which could become relevant if these grafts will be implanted in diabetic patients.  
Encouraged by these results, we are now for the first time presenting data regarding pre-clinical testing of 
stabilized ETVG grafts in a circulatory model in the rat using direct implantation as transposition grafts with 
4 and 8 week follow up and indirect implantation using the isolation-loop approach with 12 week follow-up, a 
recently validated approach as a high throughput model for testing mechanisms of endothelialization [15].  
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Materials and methods 
 
a) ETVG preparation, stabilization and characterization 
Fresh porcine kidneys were obtained from the local abattoir and stored on ice while in transit back to the 
laboratory.  The interstitial renal arteries (2.5-3.5 mm diameter, 10-15 mm length) were dissected, cleaned 
and decellularized by an alkaline treatment (0.1 M NaOH at 37 o C for 3 h).  Scaffolds were extensively rinsed 
with sterile ddH2O until the pH of rinse solutions dropped to about 8 and then finally rinsed in sterile PBS.  
Batches of scaffolds were further treated with sterile 0.1% pentagalloylglucose (PGG, Omnichem 
Ajinomoto, Belgium) in 50 mM phosphate buffer pH 5.5 containing 20% isopropanol for 24 h, rinsed and 
stored in sterile PBS.  After sterilization for 24 h in 0.1% peracetic acid in sterile PBS, scaffolds were rinsed in 
sterile PBS and stored at 4o C for up to 3 months.  Scaffold decellularization efficacy was qualitatively 
assessed by histology using DAPI nuclear staining and HematoxylineEosin (H&E) for cell nuclei and general 
matrix morphology, Masson’s trichrome for collagen and smooth muscle proteins and Voerhoff van Gieson 
(VVG) stain for elastin and biotinylated GS lectin histochemistry for a-Gal [11].  DNA was also extracted 
from fresh arterial tissue and decellularized scaffolds using a Qiagen extraction kit and samples analyzed by 
PicoGreen assay and by ethidium bromide agarose gel electrophoresis. 
 
b) Mechanical properties 
For measurement of suture retention strength, ETVG samples were cut into 5 x 10 mm segments (n = 6 per 
group) and one end was clamped to a 10 N MTS test frame (MTS Systems Corp., Eden Prairie, MN).  A single 
4-0 braided suture was placed 1 mm from the free edge and its end tied to the MTS test frame.  Samples 
were then preloaded to 0.005 N and extended to failure at 5 mm/min; final data was expressed as grams-
force. 
 
For compliance and burst pressure analysis, ETVGs (n = 6 per group) were adapted on both ends with 
barbed Luer connectors and secured with a clamp at each connector.  A peristaltic pump was used to 
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progressively fill sections with PBS at room temperature and a pressure transducer was mounted on the 
distal end of the arterial scaffold to record pressures continuously via a computer interface.  For diametrical 
compliance, segments were exposed to 80 mmHg and 120 mmHg and digital images were captured at each 
pressure setting.  The images were then imported into SolidWorks and mean outside diameter calculated 
digitally using measurements at 6 positions perpendicular to the ETVG sides.  Diametrical compliance was 
then calculated using equations published by Hamilton’s group [16].  A similar setup was used to assess burst 
pressures (n=6 per group) using the peristaltic pump to progressively fill sections with PBS until rupture. 
 
c) Scaffold heparinization 
To optimize the heparinization protocol, PGG and non-PGG treated ETVG samples were rinsed in 
phosphate buffered saline (PBS), reacted with Jeffamine, amineterminated polypropylene glycol, 
(Huntsman) 240 mM in 0.25 M MES buffer, pH = 5,2 h at room temperature using a combination of 1-Ethyl-3-
(3 dimethylaminopropyl) carbodiimide and N-hydroxysuccimimide (EDC/NHS, 300/ 10 mM) as activator.  
After another PBS rinse, nitrous acid degraded heparin (Celsius; 2 mg/ml; in 0.15 M NaCl; pH=3.9, solution 
containing 1 mg/ml NaCNBH3) was coupled by reductive amination to the aminated and non-aminated 
control samples by a 16 h reaction at room temperature.  The treatments were performed either with or 
without pre-soaking in Heparin and samples were subsequently rinsed and stored in sterile PBS. 
 
d) Heparin quantification 
The heparin content of ETVGs (n = 3) was quantitatively determined by 3methyl-2-benzothiazoninone 
hydrazone (MBTH) assay adapted from Risenfeld and Roden [17] similar to that described before by 
Bezuidenhout et al.  [18].  Heparin content (mg/g tissue) was calculated from standard curves. 
 
e) Heparinization of grafts for implantation 
Heparinized ETVG samples for implantation were prepared as described above via Jeffamine 
functionalization (without pre-soaking) and heparin attachment using 0.2μm-filtered solutions under sterile 
conditions in a laminar flow hood.  The following four implant groups were thus generated: 1) untreated 
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(None); 2) PGGtreated (PGG); 3) Heparin (Hep); and 4) PGG followed by Heparin (PGG, Hep). 
 
f) Denaturation temperature determination 
Thermograms of ETVG samples (5-10 mg, n = 3) in sealed aluminum sample pans were obtained at a 
heating rate of 10 o C/min (DSC 7; Perkin Elmer) and the onset temperature of the denaturation endotherm 
recorded as the denaturation temperature [19]. 
 
g) Resistance to enzymatic degradation 
ETVG samples (n = 6 per group and per enzyme) of about 3 x 3 mm were lyophilized and their masses 
recorded to obtain dry tissue mass.  For collagenase resistance, samples were incubated in 1 ml solution of 
20 units/mL ultrapure type VII collagenase (Sigma) in 1 mM CaCl2 100 mM Tris (hydroxymethyl) 
aminomethane at pH 7.8 and 0.02% NaN3.  For elastase resistance, samples were incubated in 1 ml of 
6.25 units/mL ultrapure elastase (Elastin Products Company) in the same buffer. 
 
After incubation at 37 o C for 24 h with mild agitation, samples were centrifuged at 12,000 RPM, rinsed three 
times with ddH2O, lyophilized and weighed to calculate percent mass loss during enzyme digestion. 
 
h) Implant groups 
For direct implants, a total of 52 rats were implanted with vascular grafts to complete a targeted n=12 per 
ETVG group, with n=6 per time point.  Three rats were replaced due to premature graft rupture at 6 weeks.  
For isolation-loop implantation, we first prepared two groups of 2.5-3 mm diameter, 10-15 mm long 
acellular grafts, namely Hep and PGG, Hep (n=6 per group) as described above.  Then we heat set 90 mm 
long low-porosity ePTFE segments for 3 min at 100o C over a spiraled 1.5 mm nylon cord to generate a 
stable alpha-loop structure without kinking.  A 10 mm midway segment was then removed from the ePTFE 
loop and replaced with a ETVG segment by end-to-end anastomosis with interrupted 90 nylon (Ethilon; 




i) Graft implantation 
All animal experiments were approved by the Animal Research and Ethics Committee of the University of 
Cape Town and were in compliance with the Guide for the Care and Use of Laboratory Animals, Institute of 
Laboratory Animal Resources, Commission on Life Sciences, National Research Council, South Africa.  Male 
Wistar rats weighing 350-510 g were induced with isoflurane 5% anesthesia and were maintained with 2% 
isoflurane spontaneously breathing via a conical mask.  Sterility was maintained throughout the procedure 
and a warming pad was used to regulate temperature.  Following a mid-line laparotomy, the aorta was 
dissected free of the inferior vena cava and surrounding tissues and all perforating arteries between the 
left renal artery and the iliac bifurcation were ligated.  In all cases the inferior mesenteric artery was 
preserved.  A single dose of intravenous heparin (1 mg/kg) was administered and the direct grafts were 
implanted into the infrarenal aorta by end-to-end anastomoses using 9-0 Nylon interrupted sutures.  The 
isolation-looped grafts were similarly implanted by anastomoses to the infrarenal aorta and further secured 
with a suture to the lumbar muscles to prevent twisting.  The abdomen was closed in layers and 
Buprenorphine (0.1 mg/kg) was administered subcutaneously twice daily for three days.  No anticoagulation 
medication was administered after surgery. 
 
j) Graft removal 
Following 4 and 8 weeks for direct implants and 12 weeks for isolation-loop implants, the abdomen was 
opened and the grafts inspected for patency by observation of pulsation in the distal aorta, under general 
anesthesia as for the implant procedure.  Animals were euthanized by exsanguination following 1 mg/kg 
heparin administration via the inferior vena cava.  The aorta was flushed with phosphatebuffered solution via 
the apex of the left ventricle until clear of blood (cca.150 ml), following which the aorta was perfusion fixed with 
formalin.  The graft was then excised, cross-sectioned for macro-photography and processed for histology. 
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k) Histology and quantification 
Tissue samples were post fixed in zinc solution [20], dehydrated, embedded in paraffin, sectioned and 
processed for histological examination.  HematoxylineEosin and Miller and Masson’s trichrome stain 
(ELMAS) were used for basic light histological analysis.  Immunofluorescent identification of endothelial cells 
was performed with antibodies to Factor 8 (Dako), CD3 for lymphocytes (Dako), ED1 for pan-macrophages 
(Serotec), CCR7 for M1 macrophages (Abcam), ED2 for M2 macrophages (Serotec), alpha-smooth muscle 
cell actin (Dako), using Cy3 conjugated streptavidin or Alexa Fluor 488 GxR (Invitrogen).  
Immunohistochemistry for endothelium was also performed with anti-CD31 antibodies (Fitzgerald).  Elastin 
and calcification was identified with Orcein and Alizarin red stain respectively, and glycosaminoglycans were 
stained with Alcian blue.  Quantitative measurements of wall thickness, lumen area, internal elastic lamina 
(IEL) diameter and neo-intimal pannus overgrowth were performed on trichrome stained sections with 
Visiopharm Integrated Systems software (VIS, Visiopharm A/S, Hoersholm, Denmark) and Adobe Photoshop 
CS6 on mid-graft cross-sections. 
 
l) Statistical analysis 
Statistical tests were performed with STATA (StataCorp.  2011.  Stata Statistical Software: Release 11 
College Station, TX: StataCorp LP) Results were expressed as mean ± SD for continuous variables.  All 
continuous data was confirmed as nonparametric (Shipiro-Wilkinson) interrogated with Mann Whitney test 
for statistical significance.  Kruskal-Wallis equality-of-populations rank test was used for multiple group 
analysis.  Categorical data was tested with the Fishers exact, and the level of significance was set at p < 
0.05.  Burst pressures, diametrical compliance and enzyme resistance were  compared  using ANOVA, and 




a) Scaffold preparation and characterization 
To generate 2.5-3.5 mm diameter, 10-15 mm long vascular grafts, we dissected segmental and inter-lobar 
arteries from adult porcine kidneys and decellularized them with NaOH as reported previously with minor 
modifications [21].  Completeness of decellularization was confirmed lack of extractable DNA, absence of cell 
nuclei in histological DAPI staining (Fig.  1) and histological analysis including H&E, Trichrome, and a-Gal 
antigen lectin histochemistry, all of which depicted cells in native tissues and their absence in decellularized 
ETVGs.  Acellular renal arteries showed good pres-ervation of overall arterial matrix morphology including 
native collagen and elastin (Fig.  1).  Notable histological features of the acellular renal arteries included a 
distinct internal elastic lamina (IEL), a relatively thin media containing thin elastin and collagen fibers and a 
very thick elastin and collagen-rich adventitia.  Suture retention strengths and burst pressures of acellular 
arteries were not different from those of native arteries (Fig.  2).  However, decellularization reduced 
diametrical compliance by about 50% (Fig.  2). 
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Figure 1 Vascular scaffold data.  (A) A whole porcine kidney arterial tree is shown after it was dissected and cleaned manually.  Segmental and interlobar arteries (red squares) of 
2e 3 mm diameter and 10e15 mm length were dissected and decellularized as described in the manuscript.  Bar is 10 mm.  (B) DNA was extracted from fresh and decellularized 
(Decell) arteries and quantified using Picogreen (mg/mg, n=6 samples per group) and verified with ethidium bromide agarose gel electrophoresis (insert, n=3, S, DNA standard; F, 
fresh; D, decellularized).  (C) DAPI nuclear stain (blue) superimposed over green elastin autofluorescence was used to highlight cells in fresh arteries and (D) lack of cells in 
decellularized (Decell) grafts.  Images are representative for n=6, bars are 50 mm.  Lower panels show histology of fresh (EeH) and decellularized (JeM) arteries using H&E, (E, J), 
Masson’s trichrome (F, K), Verhoeff van Gieson (G, L), and a-Gal histochemical detection using GS lectin (H, M).  Images are representative for n=6 per group, bars are 50 mm.  
(I, N) are a-Gal histochemistry negative controls for fresh and Decell, respectively.  (For interpretation of the references to color in this figure legend, the reader is referred to the 




Figure 2 Characterization and stabilization of acellular arterial scaffolds.  (A) Suture retention strength, (B) diametrical compliance and (C) burst pressure values for 
fresh arteries, decellularized (Decell) arteries and PGG-treated Decell arteries (PGG).  Data was obtained from n=6.  *-statistically significant as compared to fresh, 
p < 0.05.  (D) Heparin content of untreated ETVGs (-PGG) and PGG treated scaffolds (þPGG).  Groups were: Controls (C) not subjected to treatments, (H) treated 
with activated heparin alone and treated with Jeffamine (J) with and without pre-soaking in heparin (P).  (E) Graft crosslinking as evaluated by DSC test for untreated 
(-PGG) and PGG treated samples (þPGG) before (Control) and after treatment with Jeffamine (Jeff) or Heparin (Hep), or Jeff followed by Hep (Jeff þ Hep).  (F) Five 
ETVG groups were prepared and tested for resistance to enzymes: fresh renal arteries, decellularized arteries (Decell), and Decell treated with PGG alone (PGG), 
Heparin alone (Hep), and PGG followed by Hep (PGG, Hep).  n=6 per group; *-statistically significant as compared to Decell, p < 0.05.
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Table 1 Summary of direct grafts 
 
a  Excluded from quantitative analysis: 
b  Ruptured grafts (n=3). 
c Grafts explanted at designated time points which exhibited outside diameter >3.5 mm and an aortic to graft diameter ratio 
<0.4 at implant. 
 
b) Stabilization and heparinization 
 
To increase biocompatibility, untreated and PGG-treated ETVGs were heparinized by covalent 
immobilization of nitrous acid activated heparin (which contains aldehyde end-groups for end-point 
attachment).  To monitor efficacy, we measured heparin content in each group of tissues.  Simple soaking in 
activated heparin did not result in heparin binding because acellular arteries did not contain sufficient 
exposed amine groups.  Thus, we first aminated the ETVGs using diamines (Jeffamine) and carbodiimide 
chemistry.  Control samples showed low baseline levels of heparin, irrespective of PGG treatment.  No 
differences were seen between the tissue samples which were pre-soaked in heparin or not (Fig.  2).  
Significantly and much higher heparin content values were observed for samples that were first aminated 
with Jeffamine/carbodiimide prior to the reaction with heparin.  PGG did not interfere with the reaction, and 
pre-soaking in heparin did not significantly affect the heparin content of ETVGs (Fig.  2).  
Jeffamine/carbodiimide treatment alone resulted  in  significant  increases  in  denaturation  temperature (p < 
0.001) of the grafts (Fig.  2) indicative of crosslinking.  Further reaction of aminated scaffolds with activated 
heparin did induce further chemical crosslinking in both -PGG or þPGG scaffolds.  These results indicate that 
covalent immobilization of heparin cross-links the ETVGs and that PGG does not impede heparinization.  
Analysis of resistance to collagenase and elastase showed that decellularization did not significantly 
change tissue susceptibility to enzymes (p > 0.05).  PGG treatment of ETVGs reduced their susceptibility to 
elastase by about 50% while heparinization stabilized collagen by more than 80% (Fig.  2), indicating that 
PGG stabilizes elastin while heparinization treatment cross-links collagen. 
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c) Direct implants; surgical handling and implants statistics 
 
Although the surgeon was not blinded at the time of graft implant, surgical handling was adequate for all 
vascular grafts and subjectively superior in the heparinized set of grafts (Hep and PGG, Hep groups).  The 
goal of this study was to ensure completion of n = 6 implants per time point per group.  The implant 
statistics 
 
(Table 1) show that only 3 grafts ruptured prior to their scheduled 8 week explant, all of which occurred after 6 
weeks.  Two of them were from the non-stabilized graft group (“Non”) and one from the PGG-treated group.  
Rupture was confirmed at autopsy with abdominal blood and macroscopic evidence of wall defect.  These 
grafts were subsequently replaced.  After replacement, all of the animals survived to their designated explant 
time points and had 100% patent grafts (Table 1).  An overview of implantation and explanation macroscopic 
aspects is shown in Fig.  3. 
 
Direct implants; histological evaluation 
 
All grafts, irrespective of the treatments they were subjected to, demonstrated concentric peri-graft tissue 
infiltration and formation of a well vascularized collagenous granulation tissue of about 600e800 mm in 
thickness (Fig.  4).  Cells were seen infiltrating and completely re-populating the (initially acellular) graft 
adventitia without penetrating the media.  This cellular infiltration was composed of CCR7-positive (M1) and 
ED2-positive (M2) macrophages, a-smooth muscle cell actin-positive myofibroblasts, foreign body giant cells 
and very few CD3-positive lymphocytes (Fig.  4).  The thickness of this capsule did not increase from 4 to 8 
weeks and did not appear to reduce the lumen diameter, suggesting little if any constrictive remodeling.  A 
thin layer of neo-intimal tissue with the appearance of “intimal hyperplasia” but probably derived from peri-
anastomotic pannus overgrowth, was also present in all direct implants.  The neo-intimal tissue was rich in 
myofibroblasts and covered by a continuous layer of F8-positive endothelial cells (Fig.  4).  In most explants 
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analyzed, the neo-intimal tissue was stable and prevented formation of clots.  However, in about 1/3 of all 
implants, irrespective of graft pre-treatment, the neo-intimal tissue underwent detachment or remodeling at 4 
weeks, allowing for thrombus formation.  At 8 weeks, the heparizined grafts (with or without PGG) did not 
exhibit any thrombus formation.  Three neointima samples (out of total 45 analyzed) also exhibited chondroid 
metaplasia with Alcian Blue positive (not shown) and Alizarin Red positive structures (Fig.  4).  Two additional 
samples stained positive for calcium in the neointima, in the absence of chondroid metaplasia.  None of the 
acellular grafts showed any evidence of calcium deposition within the implanted graft wall. 
 
To gather more quantitative data, we analyzed representative ELMAS-stained midway graft sections by digital 
morphometry and measured the perimeter of the IEL, wall area, lumen area, wall thickness and neo-intimal 
pannus area for each sample (Fig.  5).  We also used Orcein stain for elastin and quantified the integrity of 
implanted elastin as a function of graft treatment.  When compared to pre-implant samples, the IEL diameter 
in all implanted grafts (irrespective of treatment) did not change after 4 weeks but increased significantly to 
almost 100% at 8 weeks in non-treated grafts (Fig.  6).  The IEL diameters in grafts treated with PGG, Hep or 
PGG followed by Hep remained unchanged at 8 weeks (p > 0.05).  Similarly, the luminal area was statistically 
larger only in the non-treated grafts at 8 weeks; grafts treated with PGG alone, Hep alone or PGG followed 
by Hep exhibited similar luminal areas
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Figure 3 Intra-circulatory implantation of ETVGs as direct grafts.  (A-B) macroscopic images showing grafts during implantation in the rat infrarenal abdominal 
aorta; white arrows depict the anastomoses; bar is 1 mm.  (C-F) representative macroscopic aspects of grafts before explantation (top) and macro images of 
midsections after perfusion fixation of corresponding grafts in each group (bottom).  The groups were ETVGs without pre-treatment (Non) or treated with PGG 




Figure 4 Histology of explanted direct grafts.  Representative sections shown after staining with (A) H&E, (B) Masson’s trichrome, (C) 
Alizarin red, (D) CCR7 immunofluorescence (red) for M1 macrophages, (E) ED2 stain (red) for M2 macrophages, (F) a-smooth muscle cell 
actin (red) for activated myofibroblasts in the adventitia and (G) in the neo-intima; (H) F8 endothelial stain and (I) CD3 lymphocyte stain.  
(DeI) nuclei were counterstained with DAPI (blue); Images are representative for n=6, bars are 50 mm.  AC, adventitial capsule; G, initial 
graft; P, neo-intimal pannus.  Lumen is at lower right in all images.  (For interpretation of the references to color in this figure legend, the 
reader is referred to the web  
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Figure 5 Evaluation of explanted direct graft histology.  Panel of representative Masson’s stained mid-graft histology cross-sections from each individual 
implant retrieved at 4 weeks (4 w) and 8 weeks (8 w).  ETVG groups were: untreated (Non), PGG-treated (PGG), Heparin treated (Hep) and PGG followed 
by Heparin (PGG, Hep).  Histology images were digitized and color coded to measure wall thickness (green), pannus area (yellow), lumen area (red) and 
clot (blue).  Stained sections are shown at left and corresponding digitized images at right.  (For interpretation of the references to color in this figure legend, 
the reader is referred to the web version of this article.)
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at 4 weeks without signs of progression at 8 weeks (p > 0.05).  The graft wall thickness (collagenous 
granulation tissue) was similar in most groups (600-800 mm) except for PGG, where it was thinner (p < 0.01).  
Neo-intimal pannus thickness increased across all four groups from 4 weeks to 8 weeks as a result of peri-
anastomotic tissue ingrowth (Fig.  6); however the differences among the four groups at 8 weeks were not 
statistically significant.  Notably, statistically significant preservation of elastin with sequential stabilization 
treatments was measured in ETVGs (Fig.  6E).  Both heparinization and PGG treatment independently 
resulted in a statistically significant improvement in elastin preservation (when compared to untreated 
controls) with an additive effect in their combination demonstrating that elastin, unless stabilized, is 
susceptible to in vivo degeneration.  Elastin stabilization only correlated statistically to dilatation at 8 weeks 
(Bivariate Fit, p=0.0427). 
 
Evaluation of isolation-loop (indirect) implants 
 
To test the hypothesis that the neo-intimal pannus observed in direct implants is related to trans-
anastomotic tissue ingrowth an not to transmural cell infiltration, we sutured 10 mm-long graft segments 
midway in 9 cm long ePTFE loops such that the implanted grafts were 4 cm away from the anastomosis to the 
native abdominal artery (Table 2).  The grafts were easy to suture onto the ePTFE material and they did not 
kink when forced into an alphaloop configuration (Fig.  7).  At explantation, the grafts were well integrated 
into host tissues, namely the retroperitoneum.  In the Hep group 5/6 grafts were patent while in the PGG, 
Hep group 4/6 grafts were patent. 
 
Similar to the direct implants, all isolation-loop grafts demonstrated formation of the external, well 
vascularized collagenous granulation tissue (Fig.  7).  Quantitative morphometric comparisons between the 
two pre-treatments applied to the indirect grafts (Hep vs PGG, Hep) showed that there were no significant 
differences in wall (capsule) thickness, IEL diameter (dilatation), elastin preservation and lumen area (p > 
0.05).  Similarly, no statistical differences were noted in these four parameters when indirect implant data 
were compared to the direct implant results.  The major differences between direct and indirect grafts were 







Figure 6 .  Quantitative morphometric data obtained from direct implants.  Digitized images (as shown in Fig.  5) were used to measure: (A) IEL diameter, (B) lumen area, (C) graft wall 
thickness and (D) pannus area in untreated ETVGs (Non), PGG-treated (PGG), Heparin treated (Hep) and PGG followed by Heparin (PGG, Hep).  *-statistically significant as compared 
to 4 weeks, p < 0.05.  (E) Orcein stain for elastin (top row) and quantification of elastin content from the histological images (bottom).  *-statistically significant as compared to non-
treated scaffolds (Non), p < 0.05.  G, graft.  Lumen is at top or top/right corner, bar is 50 mm. 
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Table 2 Summary for isolation-loop (indirect) grafts.   
 
samples, irrespective of the graft pre-treatment and 2) significantly reduced thrombus formation.  Since the 
arterial sub-endothelial basement membrane in the indirect grafts was not covered by pannus, this 
experiment also gave us the unique opportunity to evaluate the intrinsic thrombogenicity of the luminal 
surface of acellular arteries.  As seen in the histology, immunofluorescence and SEM images, the surface 
of the 12 week indirect implants appeared wavy but relatively smooth and free of adhered cells, fibrin 




We have shown earlier that alkaline decellularization of carotid segments removes all cells and some of the 
collagen; however, the NaOH technique was never applied to muscular arteries.  Current results on renal 
arteries demonstrate that the alkaline decellularization method was effective, with complete cell removal as 
seen on DAPI stained sections and lack of extractable DNA, as well as lack of cells on histology stains (H&E, 
trichrome, VVG).  Furthermore, acellular arteries lacked a-Gal staining which confirmed complete 
decellularization and also revealed the absence of the powerful xeno-antigen throughout the tissues. 
 
We chose renal arteries as the tissue source in order to generate size-matched grafts which would be 
implanted into the abdominal artery of rats.  In current studies we focused on acellular arteries as biological 
scaffolds for several reasons.  First, because we believed that the biggest asset of acellular scaffolds 
prepared from target tissues is the presence of an architecturally accurate extracellular matrix network 
capable of presenting cell adhesion motifs for repopulation with differentiated cells as well as to serve as 
“niches” and cues for stem cell differentiation into desired cell types [22,23].  While cell removal reduced 
immunogenicity and generated pores allowing cell infiltration, it also raised concerns regarding the 
exposure of the vascular sub-endothelial layer to flowing blood.  In current studies we showed that the sub-
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endothelial basement membrane of ETVGs was essentially non-thrombogenic.  Second, preservation of 
major tissue components (elastin and collagen) in their original configuration ensured adequate mechanical 
properties.  Our results showed that suture retention strength, handling properties and burst pressures were 
unaltered by decellularization, while compliance values were reduced by about 50% as compared to fresh 
arteries.  These results suggest that load-bearing structural components were well preserved, while other 
elements responsible for recoil (elastin associated microfibrils, proteoglycans) were probably removed by 
decellularization.  We and others have shown that among matrix components, the proteoglycans are rapidly 
lost during decellularization [14].  It remains to be determined whether these compliance levels (5-6%) will be 
important in the long run; however these values are similar to those reported by Hamilton’s group for human 
femoral and popliteal arteries (4.70-6.1%) [16].  Third, maintenance of intact, mechanically functional elastin 
within the structure of scaffolds is a very important aspect of vascular tissue engineering.  Elastin is almost 
impossible to incorporate into sheets or lamellae using a bottomeup approach and new mature elastin fibers 
are notoriously difficult to synthesize in vitro or in vivo [24,25].  Elastin is important for recoil properties of 
arterial tissues and thus its presence within our scaffolds may ensure extended mechanical durability.  
Moreover, elastin has a tendency to calcify and degenerate upon implantation and once lost in vivo, it will not 
likely be re-synthesized by resident or infiltrating cells.  For this reason we used arteries as a starting material.  
After decellularization, elastin is evident in the form of a distinct layer in the IEL, as fine fibrils within the media 
and as an extensive 3D network of fibers within the adventitia.  We then chose to treat ETVGs with PGG, an 
elastin binding polyphenol which reduces elastin’s susceptibility to enzymatic degradation and also 
diminishes its calcification potential [11,21,26-29].  Recently we also showed that PGG treatment of elastin-rich 
scaffolds protected implants from diabetes-related glycation, crosslinking and alterations in mechanical 
properties, which might prove very beneficial for diabetic patients requiring peripheral vascular surgery [10]. 
 
Acellular arterial scaffolds derived from renal arteries also contained a significant amount of collagen 
specifically in the adventitia layer.  In order to stabilize the collagen component and to increase implant 
hemocompatibility, we heparizined the scaffolds via carbodiimide chemistry.  The optimal protocol 
employed Jeffamine/carbodiimide tissue amination, followed by reaction with activated heparin, which 
yielded incorporation of significant amounts of heparin within the ETVGs (about 10% heparin by tissue 
weight).  Results also showed that PGG did not interfere with the heparinization reaction and that collagen 
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was effectively crosslinked as evidenced by increased denaturation temperatures.  Resistance to enzymatic 
degradation further confirmed that PGG stabilized elastin by reducing its susceptibility by almost 50%.  This 
effect was demonstrated earlier by us for grafts derived from carotid arteries [21].  Heparinization 
stabilized and crosslinked collagen and increased its resistance to collagenase by 3e4 fold.  Using these 
two selective stabilization techniques, we generated 4 main scaffold groups which were selected for 
implantation as direct transposition grafts in the abdominal aorta of rats and analyzed after 4 and 8 weeks: 
untreated, PGG-treated (elastin stabilized), hepariized (collagen stabilized) and PGG, heparin treated 
(elastin and collagen stabilized).  Initial studies showed that the scaffolds exhibited good handling properties 
and were easy to implant.  Survival was above 85% reaching 100% in some groups and overall patency at 
explantation was close to 100% in all groups.  Samples were analyzed by histology and the findings of this 
study could be separated into two categories; those which were unrelated to the implant treatment and those 
specific to the implant. 
 
In the first category, one major finding was encapsulation of the grafts in a concentric, peri-graft vascularized 
granulation tissue which integrated well with the scaffold adventitia but not the media.  The newly formed 
collagenous tissue stabilized at about 800 mm thickness after a few weeks and did not grow in thickness with 
time.  It is known from previous work by Campbell et al.  that implantation of solid objects (rods, tubes) into the 
peritoneal cavity or pleural cavity induces activation of macrophages and initiation of a foreign body response 
[30,31].  Infiltrating cells differentiate into myofibroblasts which generate a new connective tissue capsule rich 
in collagen surrounding the implant.  These collagen tubes were later used as vascular grafts with promising 
results [30,31].  A similar approach was used to manufacture heart valves by implanting tricuspid valve-
shaped molds subdermally in rabbits and detaching the collagenous capsule tissue [32].  In pilot studies, we 
also observed that essentially the same type of capsule is formed when ETVGs are implanted as direct 
vascular grafts in the femoral artery in minipigs (data not shown); thus it appears that this encapsulation 
reaction is non-specific and could beneficial after implantation of tubular grafts.  Notably, porcine ETVGs did 
not elicit an immune reaction after implantation in rats, strengthening
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Figure 7 Indirect isolation-loop graft evaluation.  (A) Macroscopic image of indirect graft during implantation in between two ePTFE 
looped segments (white) and (B) at explantation.  Bar is 3 mm.  (C, D) SEM analysis of the scaffold lumen surface after 12 weeks 
implantation.  G, cross section of the graft.  Bar is 100 mm in (C) and 10 mm in (D).  (E) Panel of representative Masson’s stained 
mid-graft histology cross-sections from each individual implant and ETVG group: Heparin treated (Hep) and PGG followed by 
Heparin (PGG, Hep).  Histology images were digitized and color coded to measure wall thickness (green), pannus area (yellow), 
lumen area (red) and clot (blue).  Stained sections are shown on top and corresponding digitized images below them.  (F) 
Quantitative morphometric data obtained from the indirect implants.  Groups were: Heparin treated (Hep) and PGG followed by 
Heparin (PGG, Hep) treated ETVGs.  IEL diameter, wall thickness, elastin and lumen area are shown.  Representative images of 
(G) Masson trichrome stain and (H) CD31 stain for blood vessels; bar is 50 mm.  AC, adventitial capsule; G, initial graft.  Lumen is 
at left in both images.  (For interpretation of the references to color in this figure legend, the reader is referred to the web version of 
this article.) 
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the hypothesis that xenogeneic matrices, if well decellularized, can serve as excellent tissue scaffolds 
[33,34]. 
 
Graft encapsulation occurred irrespective of the graft pretreatment, indicating that stabilization of collagen 
and elastin does not prevent cell infiltration in the adventitia.  While the adventitia was extensively 
repopulated with host cells and capillaries, few cells were found within the media of the implanted grafts.  
The mechanisms underlying this phenomenon are not known at this point, but it is possible that the 
compact IEL and adventitial elastin fibers averted cell infiltration from the lumen and adventitial sides, 
respectively. 
 
Another major finding was the omnipresence of neo-intimal tissue which grew in thickness with time, 
remodeled and in some instances calcified.  The neo-intima, potentially derived from transanastomotic tissue 
overgrowth [15,35] was covered by endothelium and thus was non-thrombogenic if intact; however, in few 
cases the neo-intimal tissue appeared disturbed, activated and associated with local thrombi.  In all samples 
analyzed calcification was absent from the scaffold graft wall, denoting the fact that decellularized arteries 
are less prone to calcification in this model.  Several aspects were noted to depend on the scaffold 
pretreatment.  Only non-stabilized grafts exhibited dilatation, associated with visible elastin degeneration in 
vivo, specifically the IEL and the adventitial elastin fibers.  PGG treatment as well as the heparinization 
crosslinking procedure both reduced elastin degeneration and the combination of the two was very effective 
in maintaining matrix integrity, pointing to stabilized arterial scaffolds as viable small diameter vascular 
grafts. 
 
Overall, this is an accepted screening model for vascular grafts with the caveat that the grafts were relatively 
short and thus were most likely endothelialized intra-luminally by trans-anastomotic tissue overgrowth.  
Because of this phenomenon, it was difficult to assess the intrinsic thrombogenicity of the graft material; thus 
we pursued a second set of implants where the trans-anastomotic tissue overgrowth was avoided by 
separating the grafts from the anastomoses by two low porosity ePTFE segments (isolation-loop model or 
indirect grafts) with follow-up at 12 weeks as described recently [15,35].  When compared to the direct grafts 
these were covered by same collagenous vascularized tissue.  However, by contradistinction to direct 
implants, the indirect grafts lacked neointimal tissue overgrowth with absence of thrombi.  These results 
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highlight the fact that the exposed sub-endothelial basement membrane of acellular arteries (derived from 
removal of the endothelium during decellularization) was essentially nonthrombogenic in this animal model. 
 
All together, these results provide data which allow us to speculate on the outcome of clinically applicable 
lengths of stabilized arterial grafts as viable small diameter vascular grafts.  Since in most clinical applications, 
segments of at least 8-10 cm long would be implanted, we expect the proximal and distal peri-anastomotic 
regions of the ETVGs to behave similar to the direct implants described in this paper and the midway section 
of the graft, at least 3-4 cm away from the anastomosis, to behave similar to the indirect implants.  Currently 
we are testing >10 cm-long, chemically stabilized small diameter ETVGs in sheep as carotid interposition 
grafts. 
 
Finally, we recommend that the optimal approach to pre-clinical testing of potential materials to be used as 
small diameter vascular grafts should include the following steps.  If the material is biologically derived, one 
should first perform adequate quality controls to ensure complete decellularization as well as preservation of 
the major extracellular matrix components, including DNA analysis, extensive histology and a-Gal analysis.  
Biologic or synthetic materials of about 2.5 mm in diameter and 10 mm length could be then tested by: 1) 
evaluating mechanical properties, including suture retention strength, burst pressure and compliance, 2) 
implanting samples subdermally in rats for initial biocompatibility, as described before [21], 3) testing tubular 
grafts as direct vascular graft implants to evaluate peri-anastomotic reactions, 4) testing as indirect isolation-
loop implants to asses host reactions away from the anastomosis and 5) implant as >10 cm long grafts in 




In the current study, we show that gentle decellularization of porcine muscular arteries generated implantable 
nonimmunogenic small diameter ETVGs endowed with adequate mechanical properties and lack of 
susceptibility towards calcification.  To increase stability in vivo, we chemically treated the elastin component 
with PGG and the collagen component with carbodiimide/heparin.  Implantation of ETVGs as vascular grafts 
in rats resulted in high patency and animal survival, possibly due to the ubiquitous encapsulation of the grafts 
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within a stable vascularized collagenous capsule and to the lack of thrombogenicity of the exposed sub-
endothelial basement membrane.  Peri-anastomotic neo-intimal tissue overgrowth was a normal occurrence 
in direct implants; however this reaction was circumvented in indirect, isolation-loop implants.  Implantation of 
non-stabilized ETVGs exhibited marked graft dilatation and elastin degeneration; however chemical 
stabilization of grafts significantly reduced elastin degradation and prevented aneurismal dilatation of vascular 
grafts in vivo without altering formation of the external capsule.  Due to their resistance to thrombosis, 
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Section III -  
 







Decades of research into synthetic small-diameter vascular grafts has resulted in little progress beyond 
surface modifications and minor design changes of pre-existing polymers (ePTFE, PET).  Recent exploration 
into tissue decellularization has shown relatives success in the laboratory, without clinicalyl relevant 
application.  This lack of translation is due to limited understanding of the in vivo healing mechanisms.  This 
study uses a three-stage screening assessment to determine in vivo healing of decellularized xenografts. 
 
Although we have previously shown that alkaline decellularization of carotid arteries removes all cells and 
some of the collagen, this technique had not been applied to muscular arteries.  We chose porcine renal 
arteries as the tissue source in this study in order to generate a size-matched xenograft for abdominal aortic 
implants in rats.  It was demonstrated that the alkaline decellularization method was effective, with complete 
cell removal and the absence of the powerful xeno-antigen throughout the tissues.  
 
The preservation of major tissue components (elastin and collagen) in their original configuration ensured 
adequate mechanical properties. Our results showed that suture retention strength, handling properties and 
burst pressures were unaltered by decellularization, while compliance values were reduced by about 50% as 
compared to fresh arteries. These results suggest that load-bearing structural components were well 
preserved, while other elements responsible for recoil (elastin associated microfibrils, proteoglycans) were 
probably removed by decellularization.  
 
Although the majority of researchers’ report on ‘bench’ as well as direct implant in vivo models, we believe 
that the short length used in these animal models have limited clinical translation.  As was shown in this 
study, an endothelialized surface in a straight interposition graft in the infra-renal rat of the aorta could not be 
replicated when isolating the graft from the anastomosis.  This is particularly relevant to human implant as 
the lack of endothelialization beyond the anastomosis has been well documented even after eleven years of 
implant[80].  It is of our opinion that anastomotic isolation models are essential for translating mid-graft 
healing to human implants. 
 
It is clear that all endothelialization described in this study occurred through transanastomotic means, 
confirmed by the lack of endothelium seen on the isolated grafts. However, the high patency and lack of 
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mural thrombus highlight the fact that the exposed sub-endothelial basement membrane of acellular arteries 
(derived from removal of the endothelium during decellularization) was essentially non- thrombogenic in this 
animal model.  Although these results should be interpreted with caution due to the inherent forgiving 
thrombogenicity of rats, the internal elastic lamina may represent a sufficiently non-thromobgenic which may 
require an endothelial layer for long term patency, a feature which would have significant impact for human 
implant. 
 
Although the rat serves as an excellent screening tool, not only are porcine and ovine models a pre-clinical 
requirement for the FDA, but the implantation of longer (clinically relevant) conduit lengths is the next logical 
step.  The highly muscular renal artery xenograft, although well suited to the infra renal rat aorta, served only 
as a proof of concept and would have little translational value to the treatment of PAD.  The abundance of 
segmental branches within the renal artery is convenient for selecting the appropriate size for implant in the 
infra renal rat aorta, however the length of each segment is limited to 20mm, negating its use for clinical 
relevant implant.  
 
We have already shown in our laboratory (unpublished data) that native bovine and femoral arteries could be 
fully decellularized, which would provide sufficient length of an infra-inguinal bypass graft in humans.  The 
mechanical properties exceed the criteria necessary for functional arteries and their limited muscular layer 
may be more conducive to transmural healing although this is speculative.  It is thus proposed that future 
research should include a large animal (ovine/porcine) model, with preference to the infra-inguinal position, 
although the carotid artery could be considered as an intermediate step due to its favorable flow dynamics. 
 
Ultimately the goal is a human implant and the conduit used in the large animal model should be carefully 
considered for this purpose.  There are only a few alternatives for small-diameter conduits of adequate 
length, such as human umbilical and cadaveric femoral vessels.  However, we believe that the tapering 
nature of the bovine mammary artery may be advantageous with a technically easier proximal anastomosis 
as well as size matched distal anastomosis negating anastomotic size mismatch.  Future experimental work 
on these theoretical properties would be required. 
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In conclusion, the implantation of non-stabilized decellularized arteries in this study exhibited marked graft 
dilatation and elastin degeneration; however chemical stabilization of grafts significantly reduced elastin 
degradation and prevented aneurismal dilatation of vascular grafts in vivo without altering formation of the 
external capsule. Due to their resistance to thrombosis, dilatation and calcification, stabilized acellular 
arteries have been shown to be promising candidates as small diameter vascular grafts through a three-
stage screening model. 
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a b s t r a c t
There is a significant need for small diameter vascular grafts to be used in peripheral vascular surgery;
however autologous grafts are not always available, synthetic grafts perform poorly and allografts and
xenografts degenerate, dilate and calcify after implantation. We hypothesized that chemical stabilization
of acellular xenogenic arteries would generate off-the-shelf grafts resistant to thrombosis, dilatation and
calcification. To test this hypothesis, we decellularized porcine renal arteries, stabilized elastin with
penta-galloyl glucose and collagen with carbodiimide/activated heparin and implanted them as trans-
position grafts in the abdominal aorta of rats as direct implants and separately as indirect, isolation-loop
implants. All implants resulted in high patency and animal survival rates, ubiquitous encapsulation
within a vascularized collagenous capsule, and exhibited lack of lumen thrombogenicity and no graft
wall calcification. Peri-anastomotic neo-intimal tissue overgrowth was a normal occurrence in direct
implants; however this reaction was circumvented in indirect implants. Notably, implantation of non-
treated control scaffolds exhibited marked graft dilatation and elastin degeneration; however PGG
significantly reduced elastin degradation and prevented aneurismal dilatation of vascular grafts. Overall
these results point to the outstanding potential of crosslinked arterial scaffolds as small diameter
vascular grafts.
Published by Elsevier Ltd.
1. Introduction
Almost 1.4million vascular grafts are needed every year in theUS
alone to replace diseased arteries. Of these, about 200,000 are small
and medium diameter grafts (4e6 mm) for vascular access and to
relieve lower limb ischemia and more than 600,000 are small
diameter grafts (1e4 mm) needed for coronary bypass procedures.
The conduit of choice for small diameter vascular graft surgery is the
autologous vein or artery, but these are not available in 25e30% of
patients due to preexisting conditions or previous harvesting [1].
Current grafts are made of polyethylene terephtalate (Dacron) or
expanded polytetrafluoroethylene (ePTFE), or biologically derived
conduits such as cryopreserved saphenous vein allografts and
decellularized bovine ureters [2,3]. Synthetic grafts are being used
successfully for replacements of large caliber arteries (above 8 mm
internal diameter) with acceptable long term patency [4]. However
when the same materials are used in small diameter applications
(less than 6 mm internal diameter), they perform very poorly as
peripheral arteries, with 50% of them occluding within 5 years,
potentially leading to amputation. This is due to the intrinsic
thrombogenicity of the materials, significant compliance mismatch
leading to peri-anastomotic intimal hyperplasia and lack of
remodeling andgrowthwhen implanted inyoungpatients [5]. Short
term results of biological grafts are also quite promising, but despite
their “off the shelf” appeal, poor 1-year patency, extended throm-
bosis, aneurysmal degeneration leading to rupture and calcification
have limited the use of such conduits [6]. This daunting lack of op-
tions has prompted surgeons to implant small diameter vascular
grafts made of synthetic polymers with suboptimal results.
Therefore, surgeons welcome the possibility of gaining access to
“off-the-shelf” small diameter grafts that would be easy to suture,
* Corresponding author. Department of Bioengineering, Clemson University, 304
Rhodes Annex, Clemson, SC 29634, USA. Tel.: þ1 864 656 5559; fax: þ1 865 656
4466.
E-mail address: dsimion@clemson.edu (D. Simionescu).
Contents lists available at ScienceDirect
Biomaterials
journal homepage: www.elsevier .com/locate/biomater ia ls
http://dx.doi.org/10.1016/j.biomaterials.2014.04.062
0142-9612/Published by Elsevier Ltd.
Biomaterials 35 (2014) 6311e6322
exhibit adequate compliance and burst pressures, remain patent
and resist thrombosis and be resistant to aneurismal degeneration
and calcification. It is believed that tissue engineering has the po-
tential to generate such viable grafts by combining synthetic or
naturally derived degradable or non-degradable scaffolds with a
variety of cells followed by maturation in bioreactors. Such con-
structs have been tested in animal models but few of them have
reached clinical trials because of their tendency to degenerate,
dilate and calcify after implantation [6e9].
To overcome aneurismal degeneration and dilatation, we hy-
pothesized that superior vascular graft scaffolds can be produced
by chemically stabilizing acellular arteries. To test this hypothesis,
we pioneered the use of elastin-rich tubular vascular grafts (ETVGs)
produced from porcine arteries fromwhich all cells and most of the
collagen has been selectively removed. This approach has the
advantage of creating a 3-D porous structure and maintaining
native tissue architecture and arterial matrix “niche” while
removing xeno-antigens. We were also the first to describe treat-
ment with pentagalloylglucose (PGG) an elastin-stabilizing poly-
phenolic tannin to reduce biodegradation and calcification of
ETVGs [10e12]. In addition we showed that PGG-treated ETVGs
exhibited adequate mechanical and biological properties in vivo by
subdermal implantation and were non-thrombogenic in acute
implantation studies in rabbits [13,14]; recently we also showed
that PGG treatment diminished the tendency of ETVGs to undergo
diabetes-related alterations in vivo [10] which could become rele-
vant if these grafts will be implanted in diabetic patients. Encour-
aged by these results, we are now for the first time presenting data
regarding pre-clinical testing of stabilized ETVG grafts in a circu-
latory model in the rat using direct implantation as transposition
grafts with 4 and 8 week follow up and indirect implantation using
the isolation-loop approach with 12 week follow-up, a recently
validated approach as a high throughput model for testing mech-
anisms of endothelialization [15].
2. Materials and methods
2.1. ETVG preparation, stabilization and characterization
Fresh porcine kidneys were obtained from the local abattoir and stored on ice
while in transit back to the laboratory. The interstitial renal arteries (2.5e3.5 mm
diameter, 10e15 mm length) were dissected, cleaned and decellularized by an
alkaline treatment (0.1 M NaOH at 37 !C for 3 h). Scaffolds were extensively rinsed
with sterile ddH2O until the pH of rinse solutions dropped to about 8 and then finally
rinsed in sterile PBS. Batches of scaffolds were further treated with sterile 0.1%
pentagalloylglucose (PGG, Omnichem Ajinomoto, Belgium) in 50 mM phosphate
buffer pH 5.5 containing 20% isopropanol for 24 h, rinsed and stored in sterile PBS.
After sterilization for 24 h in 0.1% peracetic acid in sterile PBS, scaffolds were rinsed
in sterile PBS and stored at 4 !C for up to 3months. Scaffold decellularization efficacy
was qualitatively assessed by histology using DAPI nuclear staining and Hematox-
ylineEosin (H&E) for cell nuclei and general matrix morphology, Masson’s trichrome
for collagen and smooth muscle proteins and Voerhoff van Gieson (VVG) stain for
elastin and biotinylated GS lectin histochemistry for a-Gal [11]. DNA was also
extracted from fresh arterial tissue and decellularized scaffolds using a Qiagen
extraction kit and samples analyzed by PicoGreen assay and by ethidium bromide
agarose gel electrophoresis.
2.2. Mechanical properties
For measurement of suture retention strength, ETVG samples were cut into
5"10mm segments (n¼ 6 per group) and one endwas clamped to an 10 NMTS test
frame (MTS Systems Corp., Eden Prairie, MN). A single 4-0 braided suturewas placed
1 mm from the free edge and its end tied to the MTS test frame. Samples were then
preloaded to 0.005 N and extended to failure at 5 mm/min; final data was expressed
as grams-force.
For compliance and burst pressure analysis, ETVGs (n ¼ 6 per group) were
adapted on both ends with barbed Luer connectors and securedwith a clamp at each
connector. A peristaltic pump was used to progressively fill sections with PBS at
room temperature and a pressure transducer was mounted on the distal end of the
arterial scaffold to record pressures continuously via a computer interface. For
diametrical compliance, segments were exposed to 80 mmHg and 120 mmHg and
digital images were captured at each pressure setting. The images were then im-
ported into SolidWorks and mean outside diameter calculated digitally using
measurements at 6 positions perpendicular to the ETVG sides. Diametrical
compliancewas then calculated using equations published by Hamilton’s group [16].
A similar setup was used to assess burst pressures (n ¼ 6 per group) using the
peristaltic pump to progressively fill sections with PBS until rupture.
2.3. Scaffold heparinization
To optimize the heparinization protocol, PGG and non-PGG treated ETVG sam-
ples were rinsed in phosphate buffered saline (PBS), reacted with Jeffamine, amine-
terminated polypropylene glycol, (Huntsman) 240 mM in 0.25 M MES buffer, pH ¼ 5,
2 h at room temperature using a combination of 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide and N-hydroxysuccimimide (EDC/NHS, 300/
10 mM) as activator. After another PBS rinse, nitrous acid degraded heparin (Celsus;
2 mg/ml; in 0.15 M NaCl; pH ¼ 3.9, solution containing 1 mg/ml NaCNBH3) was
coupled by reductive amination to the aminated and non-aminated control samples
by a 16 h reaction at room temperature. The treatments were performed either with
or without pre-soaking in Heparin and samples were subsequently rinsed and
stored in sterile PBS.
2.4. Heparin quantification
The heparin content of ETVGs (n ¼ 3) was quantitatively determined by 3-
methyl-2-benzothiazoninone hydrazone (MBTH) assay adapted from Risenfeld
and Roden [17] similar to that described before by Bezuidenhout et al. [18]. Heparin
content (mg/g tissue) was calculated from standard curves.
2.5. Heparinization of grafts for implantation
Heparinized ETVG samples for implantation were prepared as described above
via Jeffamine functionalization (without pre-soaking) and heparin attachment using
0.2 mm-filtered solutions under sterile conditions in a laminar flow hood. The
following four implant groups were thus generated: 1) untreated (None); 2) PGG-
treated (PGG); 3) Heparin (Hep); and 4) PGG followed by Heparin (PGG, Hep).
2.6. Denaturation temperature determination
Thermograms of ETVG samples (5e10 mg, n ¼ 3) in sealed aluminum sample
pans were obtained at a heating rate of 10 !C/min (DSC 7; Perkin Elmer) and the
onset temperature of the denaturation endotherm recorded as the denaturation
temperature [19].
2.7. Resistance to enzymatic degradation
ETVG samples (n ¼ 6 per group and per enzyme) of about 3 " 3 mm were
lyophilized and their masses recorded to obtain dry tissue mass. For collagenase
resistance, samples were incubated in 1ml solution of 20 units/mL ultrapure type VII
collagenase (Sigma) in 1 mM CaCl2 100 mM Tris (hydroxymethyl) aminomethane at
pH 7.8 and 0.02% NaN3. For elastase resistance, samples were incubated in 1 ml of
6.25 units/mL ultrapure elastase (Elastin Products Company) in the same buffer.
After incubation at 37 !C for 24 h with mild agitation, samples were centrifuged at
12,000 RPM, rinsed three times with ddH2O, lyophilized and weighed to calculate
percent mass loss during enzyme digestion.
2.8. Implant groups
For direct implants, a total of 52 rats were implanted with vascular grafts to
complete a targeted n ¼ 12 per ETVG group, with n ¼ 6 per time point. Three rats
were replaced due to premature graft rupture at 6 weeks. For isolation-loop im-
plantation, we first prepared two groups of 2.5e3 mm diameter, 10e15 mm long
acellular grafts, namely Hep and PGG, Hep (n ¼ 6 per group) as described above.
Thenwe heat set 90 mm long low-porosity ePTFE segments for 3 min at 100 !C over
a spiraled 1.5 mm nylon cord to generate a stable alpha-loop structure without
kinking. A 10 mm midway segment was then removed from the ePTFE loop and
replaced with a ETVG segment by end-to-end anastomosis with interrupted 9-
0 nylon (Ethilon; Johnson & Johnson, New Brunswick, NJ) using an operating mi-
croscope (Zeiss Universal S3 OPMI 6-SFC, Oberkochen, Germany).
2.9. Graft implantation
All animal experiments were approved by the Animal Research and Ethics
Committee of the University of Cape Town and were in compliance with the Guide
for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Re-
sources, Commission on Life Sciences, National Research Council, South Africa. Male
Wistar rats weighing 350e510 g were induced with isoflurane 5% anesthesia and
were maintained with 2% isoflurane spontaneously breathing via a conical mask.
Sterility was maintained throughout the procedure and a warming pad was used to
regulate temperature. Following a mid-line laparotomy, the aorta was dissected free
of the inferior vena cava and surrounding tissues and all perforating arteries be-
tween the left renal artery and the iliac bifurcation were ligated. In all cases the
inferior mesenteric artery was preserved. A single dose of intravenous heparin
(1 mg/kg) was administered and the direct grafts were implanted into the infrarenal
aorta by end-to-end anastomoses using 9-0 Nylon interrupted sutures. The
isolation-looped grafts were similarly implanted by anastomoses to the infrarenal
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aorta and further secured with a suture to the lumbar muscles to prevent twisting.
The abdomenwas closed in layers and Buprenorphine (0.1 mg/kg) was administered
subcutaneously twice daily for three days. No anticoagulation medication was
administered after surgery.
2.10. Graft removal
Following 4 and 8 weeks for direct implants and 12 weeks for isolation-loop
implants, the abdomen was opened and the grafts inspected for patency by obser-
vation of pulsation in the distal aorta, under general anesthesia as for the implant
procedure. Animals were euthanized by exsanguination following 1 mg/kg heparin
administration via the inferior vena cava. The aorta was flushed with phosphate-
buffered solution via the apex of the left ventricle until clear of blood (cca.150 ml),
following which the aorta was perfusion fixed with formalin. The graft was then
excised, cross-sectioned for macro-photography and processed for histology.
2.11. Histology and quantification
Tissue samples were post fixed in zinc solution [20], dehydrated, embedded in
paraffin, sectioned and processed for histological examination. HematoxylineEosin
and Miller and Masson’s trichrome stain (ELMAS) were used for basic light histo-
logical analysis. Immunofluorescent identification of endothelial cells was per-
formedwith antibodies to Factor 8 (Dako), CD3 for lymphocytes (Dako), ED1 for pan-
macrophages (Serotec), CCR7 for M1 macrophages (Abcam), ED2 for M2 macro-
phages (Serotec), alpha-smooth muscle cell actin (Dako), using Cy3 conjugated
streptavidin or Alexa Fluor 488 GxR (Invitrogen). Immunohistochemistry for
endotheliumwas also performed with anti-CD31 antibodies (Fitzgerald). Elastin and
calcification was identified with Orcein and Alizarin red stain respectively, and
glycosaminoglycans were stained with Alcian blue. Quantitative measurements of
wall thickness, lumen area, internal elastic lamina (IEL) diameter and neo-intimal
pannus overgrowth were performed on trichrome stained sections with Visio-
pharm Integrated Systems software (VIS, Visiopharm A/S, Hoersholm, Denmark) and
Adobe Photoshop CS6 on mid-graft cross-sections.
2.12. Statistical analysis
Statistical tests were performed with STATA (StataCorp. 2011. Stata Statistical
Software: Release 11 College Station, TX: StataCorp LP) Results were expressed as
mean ! SD for continuous variables. All continuous data was confirmed
as nonparametric (ShipiroeWilkinson) interrogated with Mann Whitney test for
statistical significance. KruskaleWallis equality-of-populations rank test was
used for multiple group analysis. Categorical data was tested with the
Fishers exact, and the level of significance was set at p < 0.05. Burst pressures,
diametrical compliance and enzyme resistance were compared using
ANOVA, and effect of heparinization and denaturation temperatures with stu-
dent’s t-test.
3. Results
3.1. Scaffold preparation and characterization
To generate 2.5e3.5 mm diameter, 10e15 mm long vascular
grafts, we dissected segmental and inter-lobar arteries from adult
porcine kidneys and decellularized them with NaOH as reported
previously with minor modifications [21]. Completeness of decel-
lularization was confirmed lack of extractable DNA, absence of cell
nuclei in histological DAPI staining (Fig. 1) and histological analysis
including H&E, Trichrome, and a-Gal antigen lectin histochemistry,
all of which depicted cells in native tissues and their absence in
decellularized ETVGs. Acellular renal arteries showed good pres-
ervation of overall arterial matrix morphology including native
collagen and elastin (Fig. 1). Notable histological features of the
acellular renal arteries included a distinct internal elastic lamina
(IEL), a relatively thin media containing thin elastin and collagen
fibers and a very thick elastin and collagen-rich adventitia. Suture
retention strengths and burst pressures of acellular arteries were
not different from those of native arteries (Fig. 2). However,
decellularization reduced diametrical compliance by about 50%
(Fig. 2).
Fig. 1. Vascular scaffold data. (A) A whole porcine kidney arterial tree is shown after it was dissected and cleaned manually. Segmental and interlobar arteries (red squares) of 2e
3 mm diameter and 10e15 mm length were dissected and decellularized as described in the manuscript. Bar is 10 mm. (B) DNAwas extracted from fresh and decellularized (Decell)
arteries and quantified using Picogreen (mg/mg, n ¼ 6 samples per group) and verified with ethidium bromide agarose gel electrophoresis (insert, n ¼ 3, S, DNA standard; F, fresh; D,
decellularized). (C) DAPI nuclear stain (blue) superimposed over green elastin autofluorescence was used to highlight cells in fresh arteries and (D) lack of cells in decellularized
(Decell) grafts. Images are representative for n ¼ 6, bars are 50 mm. Lower panels show histology of fresh (EeH) and decellularized (JeM) arteries using H&E, (E, J), Masson’s
trichrome (F, K), Verhoeff van Gieson (G, L), and a-Gal histochemical detection using GS lectin (H, M). Images are representative for n ¼ 6 per group, bars are 50 mm. (I, N) are a-Gal
histochemistry negative controls for fresh and Decell, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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Fig. 2. Characterization and stabilization of acellular arterial scaffolds. (A) Suture retention strength, (B) diametrical compliance and (C) burst pressure values for fresh arteries, decellularized (Decell) arteries and PGG-treated Decell
arteries (PGG). Data was obtained from n ¼ 6. *-statistically significant as compared to fresh, p < 0.05. (D) Heparin content of untreated ETVGs ("PGG) and PGG treated scaffolds (þPGG). Groups were: Controls (C) not subjected to
treatments, (H) treated with activated heparin alone and treated with Jeffamine (J) with and without pre-soaking in heparin (P). (E) Graft crosslinking as evaluated by DSC test for untreated ("PGG) and PGG treated samples (þPGG)
before (Control) and after treatment with Jeffamine (Jeff) or Heparin (Hep), or Jeff followed by Hep (Jeff þ Hep). (F) Five ETVG groups were prepared and tested for resistance to enzymes: fresh renal arteries, decellularized arteries
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3.2. Stabilization and heparinization
To increase biocompatibility, untreated and PGG-treated ETVGs
were heparinized by covalent immobilization of nitrous acid acti-
vated heparin (which contains aldehyde end-groups for end-point
attachment). To monitor efficacy, we measured heparin content in
each group of tissues. Simple soaking in activated heparin did not
result in heparin binding because acellular arteries did not contain
sufficient exposed amine groups. Thus, we first aminated the ETVGs
using diamines (Jeffamine) and carbodiimide chemistry. Control
samples showed low baseline levels of heparin, irrespective of PGG
treatment. No differences were seen between the tissue samples
which were pre-soaked in heparin or not (Fig. 2). Significantly and
much higher heparin content values were observed for samples
that were first aminated with Jeffamine/carbodiimide prior to the
reaction with heparin. PGG did not interfere with the reaction, and
pre-soaking in heparin did not significantly affect the heparin
content of ETVGs (Fig. 2). Jeffamine/carbodiimide treatment alone
resulted in significant increases in denaturation temperature
(p < 0.001) of the grafts (Fig. 2) indicative of crosslinking. Further
reaction of aminated scaffolds with activated heparin did induce
further chemical crosslinking in both !PGG or þPGG scaffolds.
These results indicate that covalent immobilization of heparin
cross-links the ETVGs and that PGG does not impede heparin-
ization. Analysis of resistance to collagenase and elastase showed
that decellularization did not significantly change tissue suscepti-
bility to enzymes (p > 0.05). PGG treatment of ETVGs reduced their
susceptibility to elastase by about 50% while heparinization stabi-
lized collagen by more than 80% (Fig. 2), indicating that PGG sta-
bilizes elastin while heparinization treatment cross-links collagen.
3.3. Direct implants; surgical handling and implants statistics
Although the surgeon was not blinded at the time of graft
implant, surgical handling was adequate for all vascular grafts and
subjectively superior in the heparinized set of grafts (Hep and PGG,
Hep groups). The goal of this study was to ensure completion of
n ¼ 6 implants per time point per group. The implant statistics
Table 1
Summary of direct grafts.
4 w 8 w Ruptured Replaced Survival at 4 w (%) Survival at 8 w (%) Excludeda Analyzed
Non 6 8 2 2 85 92 2b 12
PGG 6 8 1 1 100 100 3c þ 1b 10
Hep 6 6 0 0 100 100 1c 11
PGG, Hep 6 6 0 0 100 100 0 12
a Excluded from quantitative analysis:
b Ruptured grafts (n ¼ 3).
c Grafts explanted at designated time points which exhibited outside diameter >3.5 mm and an aortic to graft diameter ratio <0.4 at implant.
Fig. 3. Intra-circulatory implantation of ETVGs as direct grafts. (AeB) macroscopic images showing grafts during implantation in the rat infrarenal abdominal aorta; white arrows
depict the anastomoses; bar is 1 mm. (CeF) representative macroscopic aspects of grafts before explantation (top) and macro images of midsections after perfusion fixation of
corresponding grafts in each group (bottom). The groups were ETVGs without pre-treatment (Non) or treated with PGG alone (PGG), Heparin alone (Hep), and PGG followed by Hep
(PGG, Hep). White arrows depict the anastomoses and bar in (CeF) is 1 mm.
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(Table 1) show that only 3 grafts ruptured prior to their scheduled 8
week explant, all of which occurred after 6 weeks. Two of them
were from the non-stabilized graft group (“Non”) and one from the
PGG-treated group. Rupture was confirmed at autopsy with
abdominal blood and macroscopic evidence of wall defect. These
grafts were subsequently replaced. After replacement, all of the
animals survived to their designated explant time points and had
100% patent grafts (Table 1). An overview of implantation and
explantation macroscopic aspects is shown in Fig. 3.
3.4. Direct implants; histological evaluation
All grafts, irrespective of the treatments they were subjected to,
demonstrated concentric peri-graft tissue infiltration and forma-
tion of a well vascularized collagenous granulation tissue of about
600e800 mm in thickness (Fig. 4). Cells were seen infiltrating and
completely re-populating the (initially acellular) graft adventitia
without penetrating the media. This cellular infiltration was
composed of CCR7-positive (M1) and ED2-positive (M2) macro-
phages, a-smoothmuscle cell actin-positivemyofibroblasts, foreign
body giant cells and very few CD3-positive lymphocytes (Fig. 4).
The thickness of this capsule did not increase from 4 to 8weeks and
did not appear to reduce the lumen diameter, suggesting little if any
constrictive remodeling. A thin layer of neo-intimal tissue with the
appearance of “intimal hyperplasia” but probably derived from
peri-anastomotic pannus overgrowth, was also present in all direct
implants. The neo-intimal tissue was rich in myofibroblasts and
covered by a continuous layer of F8-positive endothelial cells
(Fig. 4). In most explants analyzed, the neo-intimal tissue was
stable and prevented formation of clots. However, in about 1/3 of all
implants, irrespective of graft pre-treatment, the neo-intimal tissue
underwent detachment or remodeling at 4 weeks, allowing for
thrombus formation. At 8 weeks, the heparizined grafts (with or
without PGG) did not exhibit any thrombus formation. Three neo-
intima samples (out of total 45 analyzed) also exhibited chondroid
metaplasia with Alcian Blue positive (not shown) and Alizarin Red
positive structures (Fig. 4). Two additional samples stained positive
for calcium in the neointima, in the absence of chondroid meta-
plasia. None of the acellular grafts showed any evidence of calcium
deposition within the implanted graft wall.
To gather more quantitative data, we analyzed representative
ELMAS-stained midway graft sections by digital morphometry and
measured the perimeter of the IEL, wall area, lumen area, wall
thickness and neo-intimal pannus area for each sample (Fig. 5). We
also used Orcein stain for elastin and quantified the integrity of
implanted elastin as a function of graft treatment.
When compared to pre-implant samples, the IEL diameter in all
implanted grafts (irrespective of treatment) did not change after 4
weeks but increased significantly to almost 100% at 8 weeks in non-
treated grafts (Fig. 6). The IEL diameters in grafts treated with PGG,
Hep or PGG followed by Hep remained unchanged at 8 weeks
(p> 0.05). Similarly, the luminal area was statistically larger only in
the non-treated grafts at 8 weeks; grafts treated with PGG alone,
Hep alone or PGG followed by Hep exhibited similar luminal areas
Fig. 4. Histology of explanted direct grafts. Representative sections shown after staining with (A) H&E, (B) Masson’s trichrome, (C) Alizarin red, (D) CCR7 immunofluorescence (red)
for M1 macrophages, (E) ED2 stain (red) for M2 macrophages, (F) a-smooth muscle cell actin (red) for activated myofibroblasts in the adventitia and (G) in the neo-intima; (H) F8
endothelial stain and (I) CD3 lymphocyte stain. (DeI) nuclei were counterstained with DAPI (blue); Images are representative for n ¼ 6, bars are 50 mm. AC, adventitial capsule; G,
initial graft; P, neo-intimal pannus. Lumen is at lower right in all images. (For interpretation of the references to color in this figure legend, the reader is referred to the web version
of this article.)
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at 4 weeks without signs of progression at 8 weeks (p > 0.05). The
graft wall thickness (collagenous granulation tissue) was similar in
most groups (600e800 mm) except for PGG, where it was thinner
(p < 0.01). Neo-intimal pannus thickness increased across all four
groups from 4 weeks to 8 weeks as a result of peri-anastomotic
tissue ingrowth (Fig. 6); however the differences among the four
groups at 8 weeks were not statistically significant. Notably, sta-
tistically significant preservation of elastin with sequential stabili-
zation treatments was measured in ETVGs (Fig. 6E). Both
heparinization and PGG treatment independently resulted in a
statistically significant improvement in elastin preservation (when
compared to untreated controls) with an additive effect in their
combination demonstrating that elastin, unless stabilized, is sus-
ceptible to in vivo degeneration. Elastin stabilization only corre-
lated statistically to dilatation at 8 weeks (Bivariate Fit, p¼ 0.0427).
3.5. Evaluation of isolation-loop (indirect) implants
To test the hypothesis that the neo-intimal pannus observed in
direct implants is related to trans-anastomotic tissue ingrowth and
not to trans-mural cell infiltration, we sutured 10 mm-long graft
segmentsmidway in 9 cm long ePTFE loops such that the implanted
grafts were 4 cm away from the anastomosis to the native
abdominal artery (Table 2). The grafts were easy to suture onto the
ePTFE material and they did not kink when forced into an alpha-
loop configuration (Fig. 7). At explantation, the grafts were well
integrated into host tissues, namely the retroperitoneum. In the
Hep group 5/6 grafts were patent while in the PGG, Hep group 4/6
grafts were patent.
Similar to the direct implants, all isolation-loop grafts demon-
strated formation of the external, well vascularized collagenous
granulation tissue (Fig. 7). Quantitativemorphometric comparisons
between the two pre-treatments applied to the indirect grafts (Hep
vs PGG, Hep) showed that there were no significant differences in
wall (capsule) thickness, IEL diameter (dilatation), elastin preser-
vation and lumen area (p > 0.05). Similarly, no statistical differ-
ences were noted in these four parameters when indirect implant
data were compared to the direct implant results. The major dif-
ferences between direct and indirect grafts were 1) the complete
lack of neo-intimal pannus tissue formation in the isolation-loop
Fig. 5. Evaluation of explanted direct graft histology. Panel of representative Masson’s stained mid-graft histology cross-sections from each individual implant retrieved at 4 weeks
(4 w) and 8 weeks (8 w). ETVG groups were: untreated (Non), PGG-treated (PGG), Heparin treated (Hep) and PGG followed by Heparin (PGG, Hep). Histology images were digitized
and color coded to measure wall thickness (green), pannus area (yellow), lumen area (red) and clot (blue). Stained sections are shown at left and corresponding digitized images at
right. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 6. Quantitative morphometric data obtained from direct implants. Digitized images (as shown in Fig. 5) were used to measure: (A) IEL diameter, (B) lumen area, (C) graft wall thickness and (D) pannus area in untreated ETVGs
(Non), PGG-treated (PGG), Heparin treated (Hep) and PGG followed by Heparin (PGG, Hep). *-statistically significant as compared to 4 weeks, p < 0.05. (E) Orcein stain for elastin (top row) and quantification of elastin content from the
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samples, irrespective of the graft pre-treatment and 2) significantly
reduced thrombus formation. Since the arterial sub-endothelial
basement membrane in the indirect grafts was not covered by
pannus, this experiment also gave us the unique opportunity to
evaluate the intrinsic thrombogenicity of the luminal surface of
acellular arteries. As seen in the histology, immunofluorescence
and SEM images, the surface of the 12 week indirect implants
appeared wavy but relatively smooth and free of adhered cells,
fibrin strands or microthrombi (Fig. 7).
4. Discussions
We have shown earlier that alkaline decellularization of carotid
segments removes all cells and some of the collagen; however the
NaOH technique was never applied to muscular arteries. Current
results on renal arteries demonstrate that the alkaline decellulari-
zation method was effective, with complete cell removal as seen on
DAPI stained sections and lack of extractable DNA, as well as lack of
cells on histology stains (H&E, trichrome, VVG). Furthermore,
acellular arteries lacked a-Gal staining which confirmed complete
decellularization and also revealed the absence of the powerful
xeno-antigen throughout the tissues.
We chose renal arteries as the tissue source in order to generate
size-matched grafts which would be implanted into the abdominal
artery of rats. In current studies we focused on acellular arteries as
biological scaffolds for several reasons. First, because we believed
that the biggest asset of acellular scaffolds prepared from target
tissues is the presence of an architecturally accurate extracellular
matrix network capable of presenting cell adhesion motifs for
repopulationwith differentiated cells as well as to serve as “niches”
and cues for stem cell differentiation into desired cell types [22,23].
While cell removal reduced immunogenicity and generated pores
allowing cell infiltration, it also raised concerns regarding the
exposure of the vascular sub-endothelial layer to flowing blood. In
current studies we showed that the sub-endothelial basement
membrane of ETVGs was essentially non-thrombogenic. Second,
preservation of major tissue components (elastin and collagen) in
their original configuration ensured adequate mechanical proper-
ties. Our results showed that suture retention strength, handling
properties and burst pressures were unaltered by decellularization,
while compliance values were reduced by about 50% as compared
to fresh arteries. These results suggest that load-bearing structural
components were well preserved, while other elements respon-
sible for recoil (elastin associated microfibrils, proteoglycans) were
probably removed by decellularization. We and others have shown
that among matrix components, the proteoglycans are rapidly lost
during decellularization [14]. It remains to be determined whether
these compliance levels (5e6%) will be important in the long run;
however these values are similar to those reported by Hamilton’s
group for human femoral and popliteal arteries (4.7e6.1%) [16].
Third, maintenance of intact, mechanically functional elastinwithin
the structure of scaffolds is a very important aspect of vascular
tissue engineering. Elastin is almost impossible to incorporate into
sheets or lamellae using a bottomeup approach and new mature
elastin fibers are notoriously difficult to synthesize in vitro or
in vivo [24,25]. Elastin is important for recoil properties of arterial
tissues and thus its presence within our scaffolds may ensure
extended mechanical durability. Moreover, elastin has a tendency
to calcify and degenerate upon implantation and once lost in vivo, it
will not likely be re-synthesized by resident or infiltrating cells. For
this reason we used arteries as a starting material. After decellu-
larization, elastin is evident in the form of a distinct layer in the IEL,
as fine fibrils within the media and as an extensive 3D network of
fibers within the adventitia. We then chose to treat ETVGs with
PGG, an elastin binding polyphenol which reduces elastin’s sus-
ceptibility to enzymatic degradation and also diminishes its calci-
fication potential [11,21,26e29]. Recently we also showed that PGG
treatment of elastin-rich scaffolds protected implants from
diabetes-related glycation, crosslinking and alterations in me-
chanical properties, which might prove very beneficial for diabetic
patients requiring peripheral vascular surgery [10].
Acellular arterial scaffolds derived from renal arteries also
contained a significant amount of collagen specifically in the
adventitia layer. In order to stabilize the collagen component and
to increase implant hemocompatibility, we heparizined the scaf-
folds via carbodiimide chemistry. The optimal protocol employed
Jeffamine/carbodiimide tissue amination, followed by reaction
with activated heparin, which yielded incorporation of significant
amounts of heparin within the ETVGs (about 10% heparin by tissue
weight). Results also showed that PGG did not interfere with the
heparinization reaction and that collagen was effectively cross-
linked as evidenced by increased denaturation temperatures.
Resistance to enzymatic degradation further confirmed that PGG
stabilized elastin by reducing its susceptibility by almost 50%. This
effect was demonstrated earlier by us for grafts derived from ca-
rotid arteries [21]. Heparinization stabilized and crosslinked
collagen and increased its resistance to collagenase by 3e4 fold.
Using these two selective stabilization techniques, we generated 4
main scaffold groups which were selected for implantation as
direct transposition grafts in the abdominal aorta of rats and
analyzed after 4 and 8 weeks: untreated, PGG-treated (elastin
stabilized), heparinized (collagen stabilized) and PGG, heparin
treated (elastin and collagen stabilized). Initial studies showed
that the scaffolds exhibited good handling properties and were
easy to implant. Survival was above 85% reaching 100% in some
groups and overall patency at explantation was close to 100% in all
groups.
Samples were analyzed by histology and the findings of this
study could be separated into two categories; those which were
unrelated to the implant treatment and those specific to the
implant.
In the first category, one major finding was encapsulation of the
grafts in a concentric, peri-graft vascularized granulation tissue
which integrated well with the scaffold adventitia but not the
media. The newly formed collagenous tissue stabilized at about
800 mm thickness after a few weeks and did not grow in thickness
with time. It is known from previous work by Campbell et al. that
implantation of solid objects (rods, tubes) into the peritoneal cavity
or pleural cavity induces activation of macrophages and initiation
of a foreign body response [30,31]. Infiltrating cells differentiate
into myofibroblasts which generate a new connective tissue
capsule rich in collagen surrounding the implant. These collagen
tubes were later used as vascular grafts with promising results
[30,31]. A similar approach was used to manufacture heart valves
by implanting tricuspid valve-shaped molds subdermally in rabbits
and detaching the collagenous capsule tissue [32]. In pilot studies,
we also observed that essentially the same type of capsule is
formed when ETVGs are implanted as direct vascular grafts in the
femoral artery in minipigs (data not shown); thus it appears that
this encapsulation reaction is non-specific and could beneficial af-
ter implantation of tubular grafts. Notably, porcine ETVGs did not
elicit an immune reaction after implantation in rats, strengthening
Table 2
Summary for isolation-loop (indirect) grafts.
Implanted Ruptured Patent Analyzed
Hep 6 0 5 5
PGG, Hep 6 0 4 4
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Fig. 7. Indirect isolation-loop graft evaluation. (A) Macroscopic image of indirect graft during implantation in between two ePTFE looped segments (white) and (B) at explantation. Bar is 3 mm. (C, D) SEM analysis of the scaffold lumen
surface after 12 weeks implantation. G, cross section of the graft. Bar is 100 mm in (C) and 10 mm in (D). (E) Panel of representative Masson’s stained mid-graft histology cross-sections from each individual implant and ETVG group:
Heparin treated (Hep) and PGG followed by Heparin (PGG, Hep). Histology images were digitized and color coded to measure wall thickness (green), pannus area (yellow), lumen area (red) and clot (blue). Stained sections are shown on
top and corresponding digitized images below them. (F) Quantitative morphometric data obtained from the indirect implants. Groups were: Heparin treated (Hep) and PGG followed by Heparin (PGG, Hep) treated ETVGs. IEL diameter,
wall thickness, elastin and lumen area are shown. Representative images of (G) Masson trichrome stain and (H) CD31 stain for blood vessels; bar is 50 mm. AC, adventitial capsule; G, initial graft. Lumen is at left in both images. (For
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the hypothesis that xenogeneic matrices, if well decellularized, can
serve as excellent tissue scaffolds [33,34].
Graft encapsulation occurred irrespective of the graft pre-
treatment, indicating that stabilization of collagen and elastin
does not prevent cell infiltration in the adventitia. While the
adventitia was extensively repopulated with host cells and capil-
laries, few cells were found within the media of the implanted
grafts. The mechanisms underlying this phenomenon are not
known at this point, but it is possible that the compact IEL and
adventitial elastin fibers averted cell infiltration from the lumen
and adventitial sides, respectively.
Another major finding was the omnipresence of neo-intimal
tissue which grew in thickness with time, remodeled and in some
instances calcified. The neo-intima, potentially derived from trans-
anastomotic tissue overgrowth [15,35] was covered by endothe-
lium and thus was non-thrombogenic if intact; however, in few
cases the neo-intimal tissue appeared disturbed, activated and
associated with local thrombi. In all samples analyzed calcification
was absent from the scaffold graft wall, denoting the fact that
decellularized arteries are less prone to calcification in this model.
Several aspects were noted to depend on the scaffold pre-
treatment. Only non-stabilized grafts exhibited dilatation, associ-
ated with visible elastin degeneration in vivo, specifically the IEL
and the adventitial elastin fibers. PGG treatment as well as the
heparinization crosslinking procedure both reduced elastin
degeneration and the combination of the two was very effective in
maintaining matrix integrity, pointing to stabilized arterial scaf-
folds as viable small diameter vascular grafts.
Overall, this is an accepted screening model for vascular grafts
with the caveat that the grafts were relatively short and thus were
most likely endothelialized intra-luminally by trans-anastomotic
tissue overgrowth. Because of this phenomenon, it was difficult
to assess the intrinsic thrombogenicity of the graft material; thus
we pursued a second set of implants where the trans-anastomotic
tissue overgrowth was avoided by separating the grafts from the
anastomoses by two low porosity ePTFE segments (isolation-loop
model or indirect grafts) with follow-up at 12 weeks as described
recently [15,35]. When compared to the direct grafts these were
covered by same collagenous vascularized tissue. However, by
contradistinction to direct implants, the indirect grafts lacked neo-
intimal tissue overgrowth with absence of thrombi. These results
highlight the fact that the exposed sub-endothelial basement
membrane of acellular arteries (derived from removal of the
endothelium during decellularization) was essentially non-
thrombogenic in this animal model.
All together, these results provide data which allow us to
speculate on the outcome of clinically applicable lengths of stabi-
lized arterial grafts as viable small diameter vascular grafts. Since in
most clinical applications, segments of at least 8e10 cm long would
be implanted, we expect the proximal and distal peri-anastomotic
regions of the ETVGs to behave similar to the direct implants
described in this paper and the midway section of the graft, at least
3e4 cm away from the anastomosis, to behave similar to the in-
direct implants. Currently we are testing >10 cm-long, chemically
stabilized small diameter ETVGs in sheep as carotid interposition
grafts.
Finally, we recommend that the optimal approach to pre-clinical
testing of potential materials to be used as small diameter vascular
grafts should include the following steps. If the material is biolog-
ically derived, one should first perform adequate quality controls to
ensure complete decellularization as well as preservation of the
major extracellular matrix components, including DNA analysis,
extensive histology and a-Gal analysis. Biologic or synthetic ma-
terials of about 2.5 mm in diameter and 10 mm length could be
then tested by: 1) evaluating mechanical properties, including
suture retention strength, burst pressure and compliance, 2)
implanting samples subdermally in rats for initial biocompatibility,
as described before [21], 3) testing tubular grafts as direct vascular
graft implants to evaluate peri-anastomotic reactions, 4) testing as
indirect isolation-loop implants to asses host reactions away from
the anastomosis and 5) implant as >10 cm long grafts in large
animals for pre-clinical validation.
5. Conclusions
In the current study, we show that gentle decellularization of
porcine muscular arteries generated implantable non-
immunogenic small diameter ETVGs endowed with adequate me-
chanical properties and lack of susceptibility towards calcification.
To increase stability in vivo, we chemically treated the elastin
component with PGG and the collagen component with carbodii-
mide/heparin. Implantation of ETVGs as vascular grafts in rats
resulted in high patency and animal survival, possibly due to the
ubiquitous encapsulation of the grafts within a stable vascularized
collagenous capsule and to the lack of thrombogenicity of the
exposed sub-endothelial basement membrane. Peri-anastomotic
neo-intimal tissue overgrowth was a normal occurrence in direct
implants; however this reaction was circumvented in indirect,
isolation-loop implants. Implantation of non-stabilized ETVGs
exhibited marked graft dilatation and elastin degeneration; how-
ever chemical stabilization of grafts significantly reduced elastin
degradation and prevented aneurismal dilatation of vascular grafts
in vivo without altering formation of the external capsule. Due to
their resistance to thrombosis, dilatation and calcification, stabi-
lized acellular arteries are promising candidates as small diameter
vascular grafts.
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